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Abbreviations and acronyms  
 
ACN: Acetonitrile 
CMC: Critical micellar concentration 
CROP: Cationic Ring Opening Polymerization 
Curc: Curcumin 
DCM: Dichloromethane 
DMAP: 4-dimethylaminopyridine 
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DMF: Dimethylformamide 
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MTS: (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium) 
NMR: Nuclear Magnetic Resonance 
PBS: Phosphate Buffered Saline 
PEG: Polyethyleneglycol 
PLA: Polylactic acid 
PMOXA: Poly-2-methyl-2-oxazoline 
POXA: Poly-2-alkyl-2-oxazoline 
PVP: Polyvinylpirrolidone 
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TEM: Transmission Electron Microscopy 
TFA: Trifluoroacetic acid 
TIPS: Tri-isopropylsilane 
UPLC: Ultra Performance Liquid Chromatography 
UV: Ultraviolet 
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Riassunto 
La tesi descrive la sintesi e la caratterizzazione di nuovi prodrugs carbamoilici della Curcumina 
((1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione), un importante polifenolo 
naturale cui vengono accreditate molteplici proprietà benefiche ed un ampio spettro d’azione. 
L’utilizzo in campo farmaceutico del composto naturale tal quale è però limitato dalla sua bassa 
biodisponibilità dovuta a scarsa solubilità nei liquidi fisiologici ed a un rapido metabolismo epatico. 
Difatti, dopo somministrazione orale di Curcumina, solo tracce del composto naturale vengono 
ritrovate in circolo. L’approccio prodrug, rappresenta quindi un’utile opzione per aggirare questi 
problemi. Questo approccio è basato sulla modificazione del composto naturale mediante 
protezione bioreversibile e coniugazione a specifici sostituenti (promoieties) per ottenere le 
proprietà chimico-fisiche desiderate (solubilità, stabilità ecc). Sulla base di risultati ottenuti 
precedentemente con altri fenoli naturali, ho scelto ed utilizzato il legame carbamoilico per 
coniugare la Curcumina a due diversi tipi di promoieties, amino acidi naturali e polimeri sintetici 
poliossazolinici.  
Nello specifico, tre amminoacidi,  leucina, isoleucina e valina, sono stati selezionati come  
promoieties  più promettenti da coniugare alla Curcumina. Gli amminoacidi sono stati scelti per la 
loro affinità verso specifici trasportatori presenti a livello intestinale. Questo, dovrebbe favorire 
l’assorbimento intestinale della Curcumina a seguito della somministrazione orale dei prodrugs. 
Poiché la Curcumina possiede due gruppi idrossilici, ho scelto di  funzionalizzarne rispettivamente 
uno ed entrambi mediante coniugazione con gli amminoacidi. Sono stati sintetizzati così sei 
prodrugs della Curcumina classificabili in mono- e di-sostituiti.  
Successivamente è stata testata la stabilità della Curcumina e dei prodrugs in soluzione acquosa a 
diversi valori di pH (1 e 6.8) al fine di mimare le condizioni di stomaco e intestino. Sono state 
effettuate analisi UPLC-UV, HPLC-MS, spettroscopia UV-Vis, e 1H-NMR. Nel condurre questi 
esperimenti, ho incontrato però numerosi problemi dovuti in particolar modo alla bassa solubilità 
dei composti in acqua ed  alla loro tendenza a precipitare.  
I prodrugs hanno mostrato una maggiore stabilità in soluzioni acide, confermando le aspettative 
relative ai carbammati N-mono-sostituiti, la cui reattività è nota. In soluzioni a pH 6.8 (pH 
intestinale) sono invece state osservate alcune tracce di degradazione. 
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L’idrolisi dei derivati è stata studiata anche tramite spettroscopia 1H-NMR usando soluzioni di 
D2O/DMSO-d6 a diverse percentuali di D2O.  Nessuna traccia di degradazione dei prodrugs è stata 
osservata in queste condizioni. 
Gli esperimenti preliminari di farmacocinetica che sono stati condotti su topi modello, hanno 
inoltre provato che il derivato carbamoilico di-sostituito della Leucina è in grado di aumentare la 
biodisponibilità della Curcumina dopo somministrazione orale. 
Infine, ho verificato l’affinità della Curcumina e dei prodrugs nei confronti delle proteine 
plasmatiche. In particolare, ho effettuato saggi fluorimetrici di binding utilizzando l’albumina 
umana (HSA), importante per le sue capacità di complessamento e distribuzione di sostanze 
farmaceutiche nel sangue. Tutti i sei nuovi prodrugs hanno mostrato un’affinità elevata per 
l’albumina, superiore a quella della Curcumina stessa, ad eccezione del derivato mono-sostituito 
della leucina.   
Dall’insieme dei  risultati ottenuti dallo studio dei prodrugs descritti in questa tesi è emersa la loro 
buona distribuzione nel circolo sanguigno e un’alta stabilità nei confronti degli enzimi epatici, 
evidente soprattutto per i composti mono-sostituiti,  incoraggiandone così un potenziale  utilizzo  
in campo terapeutico.  
 
L’ultimo capitolo di questa tesi descrive la sintesi di nuovi sistemi di rilascio farmaceutico ottenuti 
mediante un processo di auto assemblaggio di prodrugs polimerici della Curcumina con 
caratteristiche anfifiliche. Anche in questo caso è stato scelto il legame carbamoilico per garantire 
la coniugazione tra i polimeri e la Curcumina. Tra i vari polimeri, la scelta è ricaduta sulle poli-2-
metil-2-ossazoline (PMOXAs) la cui somiglianza ai poli-etilenglicoli (PEGs), molto spesso utilizzati in 
questo campo, sommata ad una minore risposta immunitaria e ad una maggiore idrofilia rende 
promettente la scelta di questi composti a ruolo di promoieties. In particolare, cinque  poli-2-
metil-2-ossazoline, differenti tra loro per lunghezza della catena polimerica,  sono state coniugate 
ad un solo gruppo idrossilico della Curcumina.  
A causa dell’elevata idrofilicità dei polimeri e della alta idrofobicità della Curcumina, questi nuovi 
cinque prodrugs possono essere classificati come anfifilici. Essi hanno, infatti, mostrato la capacità 
di auto assemblare in strutture di tipo micellare in soluzioni acquose garantendo così un’elevata 
solubilità della Curcumina in condizioni simili a quelle fisiologiche.  
Il lavoro si è concentrato in particolare sulla studio della correlazione tra la lunghezza della catena 
polimerica e la capacità di auto assemblare.  
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Per tutti i derivati è stata determinata la concentrazione micellare critica (CMC), che si aggira in un 
intervallo di 10-6-10-4 M. Dai risultati emersi, il coniugato Curcumina-PMOXA30, caratterizzato da 
una CMC intorno a 10-6 M, si è dimostrato il più incline ad auto assemblare. Al contrario, sono 
state identificate CMC più alte per i coniugati Curcumina-PMOXA50 e Curcumina-PMOXA100 
dovute probabilmente ad un bilancio sfavorevole tra le parti idrofobiche e quelle idrofiliche che, 
essendo più lunghe, ostacolano il processo di micellizzazione. Dall’altra parte, il derivato 
Curcumina-PMOXA10 ha mostrato alta tendenza ad aggregare e precipitare a causa della corta 
catena polimerica che in questo caso non riesce a bilanciare l’idrofobicità della Curcumina. 
La stabilità e le dimensioni delle micelle in soluzione acquosa sono  state stimate utilizzando il light 
scattering dinamico (DLS) e la microscopia a trasmissione elettronica (TEM). La lunghezza della 
catena polimerica e la dimensione delle particelle sono risultate essere in un rapporto di inversa 
proporzionalità. Infatti, i coniugati costituiti da PMOXA20 e PMOXA30 presentano  un diametro 
intorno a 100-130 nm, mentre i coniugati con PMOXA50 e PMOXA100 mostrano diametri inferiori 
intorno a 50-30 nm.  Inoltre, tutti i coniugati, ad eccezione di Curcumina-PMOXA10, hanno 
dimostrato una buona stabilità in soluzione acquosa.  
Successivamente, ho testato il rilascio di Curcumina da ogni tipologia di micella mediante analisi 
UV-Vis in soluzione di buffer salino (PBS) a pH 7.4 ed a 37°C per mimare il pH sanguigno. Il  
coniugato Curcumina-PMOXA30 è risultato il più promettente mostrando il migliore profilo 
cinetico e favorendo il rilascio di circa il 90 % della Curcumina che costituisce la micella durante le 
prime cinque ore. Gli altri coniugati hanno invece mostrato profili diversi rilasciando, nello stesso 
intervallo di tempo, percentuali di Curcumina intorno al 10-30%.  
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Abstract 
The thesis reports the synthesis and characterization of new carbamoylic prodrugs of the natural 
bioactive polyphenol Curcumin, found in many foodstuff. Curcumin is a promising drug candidate 
because of its credited beneficial health effects and wide spectrum of action. However, the low 
bioavailability due to its poor solubility in aqueous media (i.e. physiological fluids) and to its very 
fast hepatic metabolism, greatly limits the use of Curcumin in the pharmaceutical field.   
The “prodrug approach” represents a valid solution to overcome these issues. This is based on the 
conjugation of the active compound with a specific promoiety through a bioreversible linkage. This 
modification is expected to improve the pharmacokinetic profile of the compound (prevent fast 
metabolism  and enhance bioavailability). The choice of the bioreversible linker is crucial for the 
pharmacokinetic performance of the prodrug. I chose and used a urethane linkage, which has 
been recently demonstrated by our group to be the best option to protect and enhance the 
bioavailability of natural polyphenols in vivo.  
Curcumin was conjugated with two different types of promoieties: natural amino acids and poly-2-
alkyl-oxazolines, a class of hydrophilic synthetic polymers.  
 
In particular, leucine, isoleucine and valine were selected as promoieties for the conjugation with 
Curcumin, since these amino acids show enhanced intestinal absorption due to active transport 
mechanism. The conjugation of these amino acids with Curcumin could thus improve the 
absorption of Curcumin following oral administration of the prodrug.   
Curcumin has two phenolic hydroxyl groups. I functionalized Curcumin on one and both hydroxy 
groups by conjugation with amino acids through a urethane linkage, obtaining six new prodrugs 
(mono- and di-substituted, respectively).  
The stability of the new prodrugs and of Curcumin itself in aqueous media was studied using 
different experimental approaches: UPLC-UV, HPLC/MS, UV-Vis spectroscopy and 1H-NMR. The 
study of these processes and systems was severely hindered by the solubility of the new Curcumin 
prodrugs in aqueous media which turned out to be rather poor, either under acidic or near neutral 
pH conditions, as are found in the stomach and intestine. The prodrugs proved to be more stable 
in acidic solutions as expected based on the known reactivity of the N-monosubstituted 
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carbamoylic linkage. In solutions at pH 6.8 (as found in the intestine), some degradation was 
observed. The stability of the new derivatives against hydrolysis was also studied by 1H-NMR 
spectroscopy in D2O-DMSO-d6 solutions with different D2O contents. No degradation was 
observed in these aqueous media over three hours. 
Preliminary pharmacokinetic experiments were carried out and proved that the di-substituted 
leucine carbamoyl derivative of Curcumin is capable of improving the bioavailability of the parent 
phenol in mice model.  
Finally, the affinity of these prodrugs for plasma proteins was assed, using fluorescence binding 
assays with human serum albumin (HSA), which is ubiquitous in the blood stream. All of the new 
derivatives, except for the mono-leucine prodrug, have higher affinity for HSA than Curcumin 
itself. 
From these combined data a good distribution in the blood stream and high stability against 
hepatic enzymes can be expected for the new derivatives developed with this thesis, in particular 
for the mono-functionalized compounds, which make these compounds potential candidates as 
Curcumin prodrugs.   
The last chapter of this thesis is focused on the synthesis of new drug-delivery systems obtained 
from the self-assembly of amphiphilic polymeric prodrugs of Curcumin. Also in this case a 
carbamoylic bond was chosen as the linkage between Curcumin and the polymer chain. Poly-2-
methyl-2-oxazolines (PMOXAs) were chosen as promoieties for conjugation with Curcumin 
because of their similarity to the most commonly used poly-ethylene glycols (PEGs), showing the 
same stealth effects, together with a reduced immune response, and a higher hydrophilicity. In 
particular, five poly-2-methyl-2-oxazolines of different chain length were conjugated to one 
hydroxy group of Curcumin. Because of the high hydrophilic character of the PMOXAs, these five 
new prodrugs can be classified as amphiphiles. Indeed they possess the ability to self-assemble in 
micelle-like structures when put in aqueous solution, providing good-to-excellent solubility of 
Curcumin in physiological-like media.  
The correlation between the chain length and the self-assembly ability of these prodrugs was 
investigated. All derivatives have a critical micellar concentration (CMC) in the 10-6-10-4 M range. 
Curcumin-PMOXA30 showed the highest ability to self assemble into micelles at concentrations as 
low as 10-6 M. On the contrary, conjugates with PMOXA50 and PMOXA100 resulted in a higher 
CMC value, probably due to the unfavourable hydrophilic/hydrophobic ratio, typical of longer 
polymeric chain, which prevents the self-assembly process. On the other hand the derivative 
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Curcumin-PMOXA10, showed the tendency to aggregate and precipitate in solution, probably due 
to a too pronounced hydrophobic character. 
 
The size and the stability in water of all micelles were tested using dynamic light scattering (DLS) 
and transmission electron microscopy (TEM). An inverse correlation between chain length and size 
was found. In fact, conjugates with PMOXA20 and PMOXA30 form micelles with a diameter 
around 100-130 nm, whereas analogues with PMOXA50 and PMOXA100 with diameters of about 
50-30 nm. For all conjugates, except Curcumin-PMOXA10, a good stability in aqueous 
environments was observed. 
Furthermore, I tested the release of Curcumin from each type of micelles by means of UV-Vis 
analysis. The experiments were carried out in phosphate buffered saline (PBS) at pH 7.4 and at 
37°C in order to mimic the blood pH value.  The conjugate Curcumin-PMOXA30 showed the best 
kinetic profile with around 90% of released Curcumin during five hours. The other conjugates 
showed instead a release of Curcumin around 10-30% during the same time.  
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1.1 Curcumin, the “golden spice” 
Curcumin, the common name for (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-
dione, is one of the active compounds extracted from rhizome of Curcuma Longa [Fig.1].  
This compounds has different biological activities, and has therefore been attracting increasing 
interest for its potential use as a drug. Its bioactivity range spans from antioxidant to anti-
inflammatory effect [Fig.2].  
 
Figure 1. a) Molecular structure of Curcumin and Curcumin powder. b) Representation of 
Curcuma longa and its rhizome  
 
 
 
 
 
 
Curcumin was successfully tested in several clinical trials (phase I and II) as anticancer therapeutic, 
and in the treatment of neurodegenerative diseases such as Parkinson and Alzheimer. 1–3 The 
broad spectrum of action of Curcumin is due to its chemical structure which makes Curcumin able 
to interact with several molecular targets.4 
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Figure 2.  Broad spectrum of action of Curcumin5  
 
 
 
 
 
 
From a chemical point of view, Curcumin is an amphiphilic molecule characterized by three 
specific moieties, a -diketone, two hydroxy groups and two methoxy groups, able to act as 
hydrogen-bond (H-bond) acceptor and donor. These domains are fundamental for the 
intermolecular interactions between Curcumin and its molecular targets. Moreover, the -
diketone group which is connected to the aromatic rings via an alkenyl chain of seven carbon 
atoms, makes Curcumin a good Michael acceptor in conjugate-addition reactions.4  
One of the peculiarities of this molecule is that it exists in two tautomeric forms [Fig.3] and in 
different conformations. The enol form is thermodynamically favoured in polar solvents because 
of the stabilization effect of the intramolecular H-bond.6 It is known that in polar solvent (DMSO,  
acetonitrile, alcohols) the tautomeric equilibrium is completely shifted towards the enol form, 
while in apolar solvents such as toluene, benzene or hexane, a mixture of both tautomers is 
found.7–9   
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Figure 3.  Tautomeric equilibrium of Curcumin 
 
 
 
Although in polar aprotic solvents Curcumin is found in a closed cis-enol conformation, in polar 
protic solvents the open conformation is adopted as well as in physiological environment where it 
can interact with proteins directly or via water bridge9–12 [Fig.4]. 
 
 
 
Figure 4. Different conformations of enolic tautomer of Curcumin 
 
 
 
 
Nevertheless, its high lipophilicity is envisioned as one of the reasons to explain the high number 
of interactions between Curcumin and proteins, or to justify its intercalation into cellular 
membranes.13–15  Moreover, since Curcumin is able to undergo rotamerization, it can assume 
different conformations for each molecular target.16 
 
Very interesting data were obtained in recent years from studies on the incidence of 
neurodegenerative disease in developing countries. In particular, India is the first country in which 
a very low rate of Parkinson and Alzheimer disease was observed.17,18  A possible explanation to 
this observation could be related to the high quantity of consumed Curcuma.2 
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For example, a pronounced antiamyloidogenic activity was correlated to Curcumin consumption.19 
The strong interactions between Curcumin and-amyloid can prevent the aggregation in 
pathological patches. Furthermore, molecular docking studies on acetylcholinesterase identified 
three possible sites of interaction in which Curcumin binding might cause the inhibition of the 
protein and the disaggregation of the patches.20  This mechanism of action could be responsible of 
antiAlzheimer activity of Curcumin.  
Even for the therapy of Parkinson morb Curcumin and many derivatives were tested.21 
In particular, Curcumin was modified on one and both hydroxy groups by conjugation with glucose 
and glucose acetate in order to synthesize mono- and di-glucoside derivatives.22  The effect of 
such compounds was investigated in vitro on brain tissues affected by Parkinson. Curcumin-
glucoside derivatives showed high activity because of their ability to prevent the formation of 
oligomers of -synuclein and to avoid their aggregation into fibrils.22  
Together with the studies and clinical trials on neurodegenerative diseases, Curcumin has also 
been considered for its antitumoral activity.23–26 The anti proliferative effect of Curcumin is based 
on the ability to perturb specific cellular signaling pathways.27,28 In particular, these latter include:  
- -catenine/TCF4 (T-cell factor) or LEF (lymphoid enhancing factors) system. The formation of 
-catenine/TCF complex is responsible of activation in transcription of genes involved in 
differentiation and cellular proliferation mechanism. The formation of complex is inhibited by 
Curcumin  so that cellular proliferation is stopped.29 
- Caspase 3 cell signaling and activation of gene p53. Interaction of Curcumin with these targets 
The apoptosis process is promoted by.30  
- VEGF (Vascular Endothelial Growth Factor) cellular pathway. The VEGF down-regulation by 
means of Curcumin reduces the angiogenesis process.31   
In order to enhance the anti cancer activity  and the selectivity toward specific tumors, several 
analogues of Curcumin were synthesized and tested.32–36 In particular, an enhancement of anti 
tumoral activity was showed for that analogues in which phenolic rings were removed and 
substituted with nitrogen based heterocycles.37 Similarly, anti proliferative derivatives were 
obtained by  insertion of electron withdrawing substituents in position 2 and 4 of phenol 
moieties.38  Selectivity toward specific tumors such as hepatic tumor  or breast cancer was instead 
afforded  by insertion of an aromatic domain (e.g. pyrazole, isoxazole) or an alkyl chains  on the 
methylene group in  position 5 of Curcumin.39 
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 Despite being a promising candidate for the treatment of cancer and neurodegenerative diseases, 
the use of Curcumin in the pharmacological field is limited by many issues. Unfortunately, 
Curcumin suffers from poor solubility in water (60 g/mL)  as shown by the high octanol/water 
partition coefficient (log P) of 2.3-2.6.40,41  
Moreover, Curcumin is characterized by a low bioavailability and low serum levels were identified 
after few hours from oral administration in humans even if in high doses (8-12g) of Curcumin.42 
Traces of Curcumin in the intestinal tissue and in liver were detected after oral administration in 
mice, while no traces were identified upon oral administration of Curcumin in humans.43–46 
Moreover, a fast hepatic metabolism was observed, and many different metabolites were 
detected. Glucuronide conjugates and sulphates were found after oral and intraperitoneal (i.p.) 
administration.47,48  Furthermore products of the reduction of Curcumin, such as dihydrocurcumin, 
tetrahydrocurcumin, and hexahydrocurcumin were identified.49,50  
These latter, could be responsible of some biological activities of Curcumin as antioxidant and 
antidiabetic activity.50,51  
In order to overcome these bioavailability issues, the prodrug approach and the loading of 
Curcumin in nanoparticles and liposomes were the most exploited systems in recent years.52–68  
In terms of prodrugs, several compounds were exploited, and Curcumin was conjugated via 
different bioreversible linkages to a variety of small molecules, as well as polymers.  
Piperic acid, Glycine and D-alanine were used as promoieties via conjugation to the hydroxy 
groups of Curcumin with an ester bond. Such compounds showed antibiotic activity for infectious 
diseases, especially to overcome the problem of resistance, as proved by in vitro tests.69   
Other amino acidic ester bioconjugates of Curcumin were synthesized to test the enhancement of 
solubility, as well as of other biological activities (i.e. antioxidant, antimutagenicity and radical 
scavenging).70  With respect to Curcumin, enhanced water solubility was observed for derivatives 
of Curcumin with glycine and proline, and stronger antioxidant effects for Curcumin-leucine and -
isoleucine derivatives.70 
Curcumin-polymer conjugates were synthesized using different linkages  (ester, carbamate and 
thioester) with the particular aim to increase the water solubility of the drug and to promote a 
higher antitumoral activity taking advantage from enhanced permeability and retention effect.71–75  
For example, Curcumin was conjugated via a carbamoylic bond to poly ethylenglicols (PEGs) of 
molecular weight of 750 Da and 3500 Da. A high water solubility and cytotoxycity were observed 
for both these conjugates. Unfortunately, a fast hydrolysis process in physiological like conditions 
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(PBS pH: 7.4) was shown.76  In another work, the synthesis of a Curcumin-oligoethylenglicole (OEG) 
derivative and in vitro studies were reported.77 A short OEG with chain length of 7 units was 
conjugated via thioester linkage to both of the hydroxyl groups of Curcumin. For this compound 
the ability to self assemble into micelles in aqueous environment was investigated, and antitumor 
activity due to the Curcumin release at physiological pH was observed. Hydrolysis tests were 
carried out, using the same conditions previously described  for Curcumin-PEG derivatives. In this 
case, only 30% of compound hydrolyzed over 70 hours underlying a high stability of these 
compounds.77 
From the above short account on the state of the art for possible therapeutic applications of 
Curcumin, with the limitations due to its poor bioavailability and consequent attempts to develop 
effective prodrugs, it is evident that there is presently great interest in new ways to exploit the 
biomedical potential of this popular active natural compound. My PhD project focussed on this 
goal and took advantage of the expertise in the development of prodrugs of natural phenolic 
compounds gained over the years by the research team I associated with. Specifically, I used the 
carbamoyl linkage, which in previous studies78–81 proved the best among different tested 
possibilities, as described in Chapter 2, and developed new Curcumin prodrugs belonging to two 
families depending on the promoiety used, a natural amino acid or a polyoxazoline polymer. 
Specifically, I synthesized and tested a set of Curcumin prodrugs using the natural amino acids 
leucine, isoleucine and valine as promoiety. The reactivity of these conjugates was studied under 
different experimental conditions in collaboration with the group of Dr. Mario Zoratti of the CNR 
Institute of Neuroscience and pharmacokinetic experiments were carried out by Dr. Stefano 
Dall’Acqua at the Department of Pharmaceutical Sciences of the University of Padova. The 
synthesis and behaviour of these amino acid derivatives of Curcumin are described and discussed 
in Chapter 2. 
I then synthesized and studied a set of five conjugates of Curcumin with polyoxazolines in 
collaboration with Dr. Edmondo Benetti during a eight-month stage at ETH in Zurich. The 
behaviour of such polymeric prodrugs was investigated, and all micelles were completely 
characterized in terms of size, stability and kinetic of Curcumin release. 
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CHAPTER 2 
 
Amino acidic prodrugs of 
Curcumin  
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2.1 Amino acids as promoieties 
-Amino acids are excellent compounds often used as promoieties in prodrug synthesis. 
Classification of the 20 known natural amino acids is based on the polarity/apolarity of these side 
chains. They are divided in non-polar, uncharged polar and charged polar a.a. [Fig.5]. Their use as 
promoiety in prodrugs may lead to different advantages: the improvement of drug solubility, that 
enhances physicochemical and pharmacokinetic  drug profile and the possibility to resort to oral 
administration.  
 
 
Figure 5. Natural amino acids  
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Moreover, amino acids can promote drug adsorption in the gastro intestinal environment by 
active transport processes by exploiting the affinity of transporters  to amino acids with specific 
characteristics (charged or uncharged side chains). Indeed, specific transporters of amino acids 
and oligopeptides were found in brush border membranes of intestinal epithelium cells.82 Many 
examples of amino acidic prodrugs are known in the literature and other are also in commerce as 
medicament. One of the most known prodrugs is Valtrex®, in which the antiviral drug acyclovir is 
conjugated to the amino acid valine resulting in a prodrug with enhanced bioavailability due to 
increase in intestinal uptake by action of the peptide transporter PEPT1.83,84  
PEPT1, is the most known amino acids and oligopeptide carrier, it belongs to the proton-coupled 
transporter’s family and is specific for apolar side chains.85  An increase of its expression rate in 
human tissues, in particular of colon, was noticed in the case of inflammatory bowel disease and 
cancer.86  Drugs with poor bioavailability, like e.g. methyl-dopa, when conjugated with 
phenylalanine showed a ~20 fold enhancement of their intestinal permeability due to active 
transport by PEPT1.87,88 
Amino acids characterized by uncharged lateral chains can exploit two other transporters: ATB0, 
Na+ dependent neutral amino acids transporter and LAT1, neutral amino acid transporter, mainly 
found in the central nervous system.89,90 For example, amino acidic prodrugs of ketoprofen or 
valproic acid were targeted to carrier LAT1 in order to improve their permeability of blood brain 
barrier (BBB).91,92 
In addition to the enhanced permeation of the intestinal mucosa, amino acids can improve the 
stability of prodrugs toward hydrolysis or enzymatic degradation .93,94 Drugs conjugated to amino 
acids bearing apolar long side chains e.g. leucine, isoleucine and valine, showed higher stability 
toward hydrolysis and enzymatic metabolism.95–97  This is probably due to the steric clash between 
the enzymatic pocket and the amino acid’s side chain.94 It has been demonstrated that the nature 
of the linkage between the amino acid and the drug plays a crucial role in these mechanisms.98,99  
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2.2 Carbamoylic prodrugs of polyphenols 
Different linkages are usually exploited in the synthesis of prodrugs and in particular of prodrugs 
of natural polyphenols. Several prodrugs of resveratrol, quercetine and pterostilbene [Fig.6] were 
developed and studied by my research group in order to increase the bioavailability of the natural 
active compound after oral administration.  
 
Figure 6.  Molecular structure of specific polyphenols  
 
 
 
 
In particular, acetal, sulfonate, carbonate, and carboxyester were tested, among others, as 
bioreversible linkage between drug and promoiety.100–105 Results of in vitro and in vivo 
experiments of these prodrugs showed a high rate of hydrolysis and promoted the investigation 
on other types of linkage. Eventually the carbamoylic bond was chosen as more hydrolytically 
stable linkage than ester or carbonate and tested using resveratrol as model. N-mono-substituted 
and N,N-di-substituted carbamoylic derivatives were synthesized. Resveratrol was mono-, di- and 
tri-substitued using dihydroxipropyl, 6-deoxigalactosyl, butyl-glucosyl and m-PEG350 as 
promoieties.80,81  All derivatives showed high water solubility, high hydrophilicity and good 
response to carbamoyl esterase activity of plasma albumins.80,81. In particular, the rate of 
hydrolysis for N’-monosubstituted compounds resulted much faster than N,N-disubstituted 
derivatives.106,107 The reasons of these differences are related to the different hydrolysis 
mechanism in primary and secondary carbamates.  The first undergoes hydrolysis passing through  
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the nitrogen deprotonation and the formation of an anionic intermediate [Fig.7a]. In the case of 
secondary carbamate, in which an acidic proton is absent, carboxylic group is directly attached by 
the base with consequent formation of tetrahedral intermediate108  [Fig.7b].  
So, since their good rate of hydrolysis, N’-monosubstituted carbamates were identified as best 
compounds for their use in pharmaceutical field.80,81,109 
 
Figure 7. Mechanisms of base-catalyzed hydrolysis of a) N’-monosubstituted carbamate b)N,N-
di-substituted carbamate. 
 
 
 
In another work79  resveratrol was functionalized with specific amino acids by carbamoylic bond. 
Leucine, isoleucine, threonine and phenylalanine were selected as promoieties in order to 
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enhance the water solubility of resveratrol and to investigate the intestinal uptake of these 
compounds by peptide transporter LAT1. All derivatives showed high solubility in water, however 
the enhanced polarity prevented the penetration of cellular membranes and the conjugation to 
LAT1.79 
 
2.3 Synthesis of amino acidic prodrugs of 
Curcumin 
A large part of my PhD project focussed on the synthesis of new carbamoylic prodrugs of natural 
polyphenols using amino acids as promoieties. Curcumin was chosen as polyphenol for its 
remarkable biomedical properties, as described in the Introduction, and for its well known 
problems of poor bioavailability and solubility. Among the amino acids, valine, leucine and 
isoleucine were chosen since they are known as best ligands for amino acids transporters. One and 
both the hydroxyl groups of Curcumin were functionalized in order to protect the polyphenol by 
the phase 2 conjugative metabolism during absorption after oral administration and to investigate 
the possible improvement of the ADME (absorption, distribution, metabolism and excretion) 
profile in pharmacokinetics experiments using the synthesized prodrugs. 
For the synthesis I used a procedure, reported in Scheme 1, previously established and optimized 
in my research group.79,81 
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Scheme 1.  General procedure for the synthesis of Curcumin prodrugs  
 
 
 
 
 
 
In the first step, the primary amino group of the carboxy-protected amino acid was activated by 
reaction with bis(4-nitrophenyl)carbonate in order to obtain a reactive 4-nitrophenyl urethane 
intermediate. In the second step, which was done in a one-pot procedure without isolation of the 
active urethane, transesterification with Curcumin was achieved via base promoted addition and 
elimination of 4-nitrophenol as shown in Figure 8. Finally, cleavage of the tert-butyl ester 
protecting group at the carboxyl moiety was carried out using TFA in DCM and tri-isopropylsilane 
(TIPS) as cation scavenger. 
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Figure 8. Nucleophilic substitution by Curcumin hydroxyl group on the active urethane 
intermediate with elimination of p-nitrophenol. The reaction is thought to proceed via and 
addition/elimination sequence. 
 
 
 
 
 
To obtain the mono- or di-substituted products, either one or 0.5 equivalents of Curcumin, 
respectively, were added to the reaction mixture during the second step. 
The obtained products were purified by flash chromatography in order to isolate mono- or di-
substituted derivatives. Each derivative was then characterized by proton and carbon NMR and by 
ESI/MS spectrometry. NMR experiments were carried out using DMSO-d6 as solvent in order to 
shift largely the tautomeric equilibrium towards a single tautomer, the enol form, thus simplifying 
the spectrum and signal assignments as in the Curcumin spectrum showed in Figure 9 below. The 
signal of the enolic proton O-H under these conditions is not observed because of its tendency to 
be involved in hydrogen bonds which promotes the shift of this signal around 12-16 ppm.7,109 The 
existence of Curcumin as enol tautomer is confirmed by the signal of the methylenic proton at 6.2 
ppm whose integration results in a single proton as expected for this tautomer. Furthermore, as 
additional evidence of the existence of the enol tautomer, in the 13C-NMR spectrum of Curcumin it 
is possible to observe the signal of carbon linked to the enol group around 180 ppm [Fig. 9b]. 
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Figure 9.  a) 1H-NMR  (300 MHz,  DMSO-d6) and b)13C-NMR (300 MHz,  DMSO-d6) of Curcumin 
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Proton NMR spectra confirmed the achievement of the desired product by identification, among 
others, of the signal of the carbamoylic proton –NH in a range between 8.0 and 8.2 ppm which 
appears as a doublet [Fig.10a]. Moreover, mono-substituted products showed a characteristic 
signal at 9.67 ppm, which can be ascribed to the phenolic proton –OH and an increased complexity 
in the pattern of the aromatic protons in the range 6.13 - 7.63 ppm, consequence of the loss of 
symmetry in the molecule if compared to the starting material (Curcumin) or to the corresponding 
di-substituted product as shown in Figure 10b. 
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Figure 10. a) 1H-NMR (300 MHz,  DMSO-d6) of Curc-m-LeutBuO  b) Comparison of aromatic 
signals in 1H-NMR spectra between Curc-m-LeutBuO (left) and Curc-d-LeutBuO (right)  
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After deprotection with TFA and tri-isopropylsilane, the final products 1a – 1c and 2a – 2c were 
obtained. Each was isolated by flash chromatography and purified by preparative HPLC using 
acetonitrile/water with 0.05% of trifluoroacetic acid and a gradient of eluent composition starting 
from 20% and reaching 100% acetonitrile. All compounds were then characterized by proton and 
carbon NMR and by ESI/MS spectrometry.  
Following this procedure, six amino acidic derivatives of Curcumin were synthesized [Fig.11]. 
 
Figure 11. Molecular structures of the new six amino acidic prodrugs of Curcumin 
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2.4  Hydrolytic reactivity of Curcumin and 
derivatives 1a-c and 2a-c 
The hydrolytic reactivity and degradation processes of Curcumin have been extensively 
investigated but not yet fully characterized and understood as testified by a vast, yet conflicting 
literature.2,6,109-111 I therefore decided to test the stability of Curcumin itself besides that of its 
amino acid prodrugs under specific conditions relevant for their possible use via oral 
administration. 
In particular, the stability of the synthesized new derivatives and of Curcumin itself was tested in 
aqueous solutions at pH 1 and 6.8 at 37°C, to match conditions found in the physiological 
environment of stomach and gut, respectively. The hydrolytic reactivity of Curcumin was assessed 
by UV-Vis spectroscopy and HPLC/MS analyses.  
 
2.4.1 UV-Vis stability assay 
The absorption maximum of Curcumin (425 nm), was determined by analysis of a standard 15 M 
solution of Curcumin in DMSO. Absorption spectra of solutions (nominally 15 M) of Curcumin at 
pH 1 and 6.8 (PBS buffer) at 37 °C were recorded every 4 hours for 24 hours. From the UV spectra, 
in acidic and in basic conditions, a decay in the Curcumin absorption at 425 nm was detected 
already after 4 hours [Fig.12a-b]. In addition, after 24 hours, Curcumin absorption was barely 
detectable and the presence of a yellow precipitate was observed in both cases. This precipitate 
was identified as Curcumin by redissolving it in DMSO and acquiring a UV-Vis spectrum. As showed 
by UV-Vis spectrum in acidic solution, two different peaks can be identified at 363 nm and 425 nm 
that can be ascribed to the diketo and the enol form of Curcumin, respectively.112-114 The diketo 
form, which, according to the literature, is the most favourable in aqueous acidic solutions, is 
more hydrophobic if compared to the enol form promoting the precipitation within the aqueous 
environment.115 The reason for this decay in absorbance could be ascribed to different factors. 
Namely, the low water solubility, especially at low pH, of Curcumin that results in its precipitation 
as a yellow solid and the possible decomposition of Curcumin. 
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Figure 12. a) UV-Vis spectra of Curcumin in PBS  pH: 6.8 b) UV-Vis spectra of Curcumin in HCl 
pH:1  
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The spectrum of each precipitate was compared to the spectrum of a Curcumin standard solution 
[Fig. 13]. An absorption peak at 425 nm was identified for both precipitates, thus confirming the 
hypothesis of precipitation. This latter is ascribed to  the Curcumin keto-enolic equilibrium that, in 
aqueous solution, promotes the formation of the keto tautomer, more hydrophobic than enol 
tautomer.8 
   
 
Figure 13. UV-Vis spectra of precipitate found at pH 1 (orange), precipitate found at pH 6.8 (blue) 
and Curcumin standard solution (grey) in DMSO 
 
 
 
 
These results indicate a good stability of Curcumin in acidic environment while a partial 
degradation and precipitation occurs under slightly alkaline conditions.  
 
2.4.2 HPLC-MS assessment of the stability of Curcumin 
 
UV-Vis data were also compared with the data acquired by HPLC-MS analysis which allows for an 
identification of the hydrolysis products. According to the literature, the major degradation 
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products of Curcumin in aqueous solution (PBS 0.1 M, pH 7.2, at 37°C) are those shown in Figure 
14.109-111 The parameters and the sample concentration used in my experiments were the same as 
used for the UV tests. A C18 column and as eluent a gradient of Acetronitrile/H2O from 10% to 
100% in 30 minutes were used.  
At pH 6.8, the appearance of five new peaks with relatively short retention times indicates a 
partial degradation although also in this case a major precipitation of the compound was observed 
as shown by the decrease in the signal intensity after 24 hours [Fig. 15]. The most part of these 
compounds was poorly ionizable under ESI conditions,  preventing their identification. In the 
chromatograms the peaks with retention times of 16 and 20.5 minutes have m/z 369 which 
corresponds to protonated Curcumin, as confirmed by their UV-Vis spectra. The presence of two 
peaks with the same mass value is attributed to the existence of a tautomeric equilibrium of 
Curcumin.  
According to the literature, the first peak, with a retention time of 16 minutes, should be related 
to the diketo tautomer.113  
The second peak is indeed representative of the enol form. This latter is considered the 
thermodynamically favoured tautomer because of intramolecular hydrogen bond and the 
presence of a conjugated  system.114,116 Moreover,  The presence of the two tautomers has been 
previously confirmed by the UV-Vis spectrum of Curcumin in HCl 0.1 N solution. The peak with m/z 
401 and retention time 10.2 minutes was attributed to compound 6  [Fig.15]. 
Other known products of the degradation of Curcumin, such as 3, 4 and 5 were not observed.    
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Figure 14. Principal degradation products of curcumin in 0.1 M phosphate buffer (PBS, pH 7.2 , T: 
37°C) reported in the literature.117 
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Figure 15.  Chromatograms obtained by HPLC/MS analysis of Curcumin in PBS (pH = 6.8) 
maintained at 37°C for 24 hours. Ranges of wavelength selected  for detection: 315-323nm and 
417-433 nm 
 
 
 
 
 
In contrast, Curcumin proved to be stable over a 24 h period in acidic solution (HCl 0.1 N, [Fig. 16]) 
where only low amount of the keto-form was detected. 
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Figure 16.  Chromatograms obtained by HPLC/MS analysis of Curcumin in HCl 0.1N (pH = 1) 
maintained at 37°C for 24 hours. Ranges of wavelength selected  for detection: 315-323nm and 
417-433 nm 
 
 
 
 
  
 40 
 
2.4.3 UPLC and HPLC-MS assessment of the stability of derivatives 1a-c and 2a-c 
 
The stability of the new amino acid prodrugs of Curcumin in aqueous solution at different pH 
values was also tested. Aqueous solutions (15 µM) were prepared by dilution in the appropriate 
media (HCl 0.1 N or PBS at pH = 6.8) of a stock solution of the derivative in DMSO in order to have 
a maximum of 15% of DMSO in the final solution. The hydrolytic stability over 24 hours of 
derivatives 1a-c and 2a-c was assessed by UPLC-UV analysis. During these experiments several 
issues emerged due to the low solubility and tendency for aggregation of these compounds and 
after one hour traces of a yellow precipitate were found in the solution. In order to better 
understand the behaviour of these prodrugs in physiological like conditions, HPLC/MS analysis 
were performed under the same conditions discussed before. Derivatives 1c and 2c were chosen 
as model compounds to study the stability. 
 
Aliquots of freshly prepared aqueous solutions were analyzed at time 0 and after 24 hours of 
incubation at 37°C. 
The monosubstituted analogue of Curcumin (1c) in PBS solution at pH 6.8 showed at time zero two 
peaks both with m/z 512 attributed to the keto and enol tautomers. After 24 hours at 37°C, about 
50 % of 1c remained unmodified as confirmed by the presence of the peak at 21.0 min, and a few 
unknown peaks appeared with low retention times [Fig. 17] indicating a certain degree of 
degradation. A trace of yellow precipitate was also observed. Mass spectrometric analysis allowed 
to identify the precipitate as curcumin confirming a slow hydrolysis of the carbamoyl linkage under 
these conditions. 
Under acidic conditions 1c showed a relatively slow degradation rate [Fig. 18] leading to a 
decrease of 25% in the derivative’s concentration after 24 hours. As in the case of the PBS solution 
at pH 6.8, two peaks with same m/z values were identified, confirming the presence of a diketo-
enol tautomerism but not curcumin was found confirming the stability of the carbamate linkage 
under acidic conditions.  
The same behaviour was also observed for the di-substituted derivative 2c confirming slow 
hydrolysis of the carbamate linker at pH 6.8 and higher stability at acidic pH. The analysis for this 
compound was made difficult by the poor water solubility compared to the mono-substituted 
analogue. 
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Figure 17.  Chromatograms obtained by HPLC/MS analysis of 1c in PBS (pH = 6.8) maintained at 
37°C for 24 hours. Ranges of wavelength selected  for detection: 315-323nm and 417-433 nm 
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Figure 18.  H Chromatograms obtained by HPLC/MS analysis of 1c in HCl 0.1N (pH = 1) 
maintained at 37°C for 24 hours. Ranges of wavelength selected  for detection: 315-323nm and 
417-433 nm  
 
 
 
 
 
 
These analyses and analogous trials with the other synthesized compounds show that all 
derivatives, as well as Curcumin, are characterized by a poor solubility in water, especially at low 
pH values and in particular for di-substituted derivative. They are stable in acidic solution and can 
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therefore survive the gastric stage. In near-neutral solution (pH 6.8) the rate of hydrolysis of the 
carbamoyl linkage is conveniently slow ensuring the protection of the phenolic function during 
absorption. 
 
2.4.4 NMR assessment of the stability of Curcumin derivatives 
 
The stability of the synthesized compounds in aqueous media was also studied by means of NMR 
analysis. Larger amounts of DMSO were used compared to those of the previously described 
stability assays in order to avoid precipitation. Compound 2b was taken as example. The 
compound was dissolved in DMSO-d6 and different amounts of D2O were added to achieve a final 
concentration of 1 mM and water percentages of 10%, 30% and 50%, respectively. It turned out, 
however, that 2b was not completely solubilized in 50% D2O-50% DMSO-d6 at this concentration. 
Therefore the data from experiments performed in this medium are not included in the present 
analysis. From NMR analysis of solutions of 2b in 10% and 30% D2O in DMSO-d6 no hydrolysis was 
observed over 3 hours at room temperature [Fig.s 19a and 20a]. 
In particular, the signals of the aromatic protons remain unchanged during the 3 hours of duration 
of the experiment [Fig.s 19b and 20b]. It is also noticed that after 1 hour in both solutions, with 
10% and 30% of D2O, respectively, complete exchange of the carbamoylic N-H proton with 
deuterium has occurred as shown by the disappearance of the characteristic signal around 7.8 
ppm [Fig.s 19b and 20b]. The signal appears as a doublet at time = 0 due to the slow exchange rate 
of carbamoylic proton which allows coupling with the proton on the α carbon of the amino acidic 
promojety.118-120 The deuterium exchange of the N-H group is confirmed by the corresponding 
changes observed in the signal of the proton on the α carbon of the amino acidic promojety 
around 3.8-3.9 ppm. At time zero, this signal appears as a multiplet centered at 3.9 ppm, due to 
spin-spin coupling of such proton with both the carbamoylic proton and the proton of the amino 
acidic side chain respectively. Spectra acquired after 1h, 2h and 3h show that the multiplicity of 
the signal changes from multiplet to doublet. This change in multiplicity is related to the N-H 
deuterium exchange which results in the disappearance of coupling with the carbamoylic N-H 
proton.
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Figure 19. a) 1H-NMR spectra (300 MHz) of 2b in a solution of 90% DMSO-d6 and 10% D2O. 
Spectra were acquired every hour for 3 hours. b) Expansion of aromatic region between 8 and 6.5 
ppm c) expansion of amino acidic -proton  
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Figure 20. a) 1H-NMR spectra (300 MHz) of 2b in a solution of solution of 60% DMSO-d6 and 30% 
D2O. Spectra were acquired every hour for 3 hours. b) Expansion of aromatic region between 8 
and 6.5 ppm  c) expansion of signal of amino acidic -proton  
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These data indicate a high hydrolytic stability of the synthesized derivatives in DMSO/water 
solutions where no precipitation occurred. Extrapolation of these results to interpret those 
acquired by HPLC analysis of Curcumin and derivatives in aqueous solutions suggests that 
precipitation processes have probably contributed to loss of signal during the UV-Vis and HPLC 
analyses more than hydrolysis and degradation processes. 
 
2.5 Pharmacokinetic profile of Curcumin and 
amino acid prodrugs 
In vitro stability studies thus indicated that the rate of hydrolysis of the carbamoyl bond in our 
new Curcumin derivatives is suitable for application as prodrugs. We therefore proceeded to 
investigate the behavior of our compounds in pharmacokinetics studies in vivo. These assays are 
carried out in collaboration with researchers at the Department of Pharmaceutical Sciences and 
are still ongoing. I report here preliminary results obtained for the mono-leucine and di-leucine 
derivatives (1a and 2a) in comparison with the natural polyphenol Curcumin. 
Following administration of a single intragastric bolus of 1a, 2a or Curcumin (50 mg/Kg suspended 
in H2O) to overnight-fasted male mice (weight between 20-25 g) aliquots (200 L) of whole blood 
were taken at specific intervals (5, 10, 30 minutes and 1, 2, 4, 6 hours) and diluted with methanol 
(200 L) to precipitate proteins. Benzanilide (100 L of 220.8 g/mL solution) was added as 
internal standard. Each sample was vortexed, centrifuged (10 minutes, 13000 rpm) and the 
supernatant was collected, concentrated under vacuum and dissolved in methanol (50 L). Then 
the resulting mixture was analyzed by UPLC-UV-MS (Agilent 1260 with Agilent/Varian 320 Triple 
Quadrupole –TQD) injecting 10 L in a C18 Phenomenex 2.6 m 2.1 x 50 mm column and using as 
eluent a gradient of Acetronitrile/H2O +2% of HCOOH from 10% to 95% ACN in 9 minutes. 
The results obtained [Fig 21] clearly indicate that the mono-substituted Curcumin derivative 1a is 
rapidly and extensively absorbed by the intestine after intragastric administration, resulting in high 
concentration in blood of the unmodified prodrug and also releasing free Curcumin during the 6 
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hours of the pharmacokinetic experiment in amounts of the same order of magnitude as when 
Curcumin was administered as such. 
Administration of the di-substituted Curcumin derivative 2a instead resulted in a sustained 
delivery of the active polyphenol Curcumin during the 6 hours of pharmacokinetics in larger 
amount (7.3 times more) as compared to the amount of Curcumin administered as such. 
These are preliminary results which need to be confirmed and extended. They might be explained 
by the low absorbtion rate of the di-substituted Curcumin analogue which transits through the gut 
slowly hydrolyzing to the mono-substituted analogue, which is in turn rapidly absorbed and 
hydrolyzed in the bloodstream to give Curcumin. 
 
Figure 21. AUC0-6h of the species circulating in the bloodstream after oral administration of 
Curcumin, 1a (mono-leucine derivative) and 2a (di-leucine derivative). Error bars represent + 
standard deviation (an error bar of the same size in the negative direction is also implied but not 
shown for graphic clarity). n = 3 
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These results suggest that carbamoyl bond-based di-substituted amino acid prodrugs of Curcumin 
might be quite effective in increasing its bioavailability. The other derivatives synthesized are 
currently under investigation. 
 
2.6 Studies about binding affinity to Human 
serum albumin 
The low solubility of prodrugs and Curcumin itself in aqueous solution, led us to investigate on 
their affinity for proteins, in particular toward human serum albumin, which is ubiquitous in the 
blood stream and is known to have function of transport for highly hydrophobic small molecules 
and peptides. Binding assays for Curcumin and all synthesized prodrugs were thus carried out. 
Human Serum Albumin (HSA) is characterized by the presence of a tryptophan residue in the 
proximity of the binding site, thus quenching of fluorescence emission at 340 nm was used as 
parameter to monitor the binding. As shown in figure 22a, the higher is the concentration of 
prodrug in HSA solution the  higher is the fluorescence quenching of protein.  
A 3 M solution of HSA in PBS at pH 7.4 and 1 mM ethanolic stock solutions of the synthesized 
new Curcumin prodrugs were prepared. The HSA solutions were maintained at 37°C and were 
titrated with aliquots of 1 L of the Curcumin prodrug (1a-c, 2a-c). After each addition an emission 
spectrum was acquired.  
The dissociation constant (Kd) of the prodrug/albumin complex was extrapolated by non-linear 
regression of the function of prodrug concentration versus percent fluorescence quenching, 
considering a 1:1 binding stoichiometry.  
 
A control experiment with Curcumin was also performed. The Kd determined in this experiment 
was 1 M in agreement with data reported in literature [Fig. 22b].121  
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Figure 22. a) Fluorescence spectra of aqueous solution of HSA at different concentration of 
Curcumin. Fluorescence quenching band of tryptophan residues at 340 nm was considered. b) 
Binding curve of Curcumin. A binding constant (Kd) of 1 M was deteremine by extrapolation of 
the curve.   
 
 
 
 
 
For the major part of the new Curcumin prodrugs developed in this thesis, the measured binding 
constants underline a strong affinity for albumin, higher than that of Curcumin, probably due to 
their hydrophobicity. As shown in Table 1 binding constants are in the 640 -730 nM range, with 
the exception of Curcumin-di-leucine which shows a significantly higher affinity, with a Kd = 225 
nM. This means that this derivative is a very strong ligand for albumin.   
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Table 1. Dissociation constants extrapolated for compounds 1a-c, 2a-c 
 
Compound Kd (nM) 
Curcumin-m-Leucine (1a) 3x104 
Curcumin-di-Leucine (2a) 225 
Curcumin-m-Isoleucine (1b) 640 
Curcumin-di-Isoleucine (2b) 709 
Curcumin-m-Valine (1c) 670 
Curcumin-di-Valine (2c) 730 
 
For the equilibrium binding constant calculation a one site binding model was used [Fig. 23]. 
 
Figure 23. Fitting of binding curve of compound 1b. The experimental curve (blue) and the fitting 
curve (red) obtained for this compound are compared. 
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The equation used for the fitting of the curves was the following: 
      
 
    
 
Where: 
Y is the experimentally determined quenching in fluorescence emission of HSA 
Bmax is the plateau value of the curve at high concentration of ligand 
C is the ligand concentration 
 
Because of the good fitting observed in all cases, which is indicative of the reliability of the 
extrapolated constants, we could conclude that all the new synthesized Curcumin prodrugs are 
able to bind to HSA more strongly than Curcumin itself.  
Curcumin-m-Leucine (1a) showed, however, a particular behavior, a high dissociation constant (30 
M) which is about 30 times higher than Curcumin, indicating the poor activity of this derivative as 
ligand for albumin if compared to the other prodrugs [Fig. 24].   
 
Figure 24.  a) Fluorescence spectra of aqueous solution of HSA at different concentration of 1a. 
Fluorescence quenching band of tryptophan residues at 340 nm was considered. 
b) Binding curve of 1a. A binding constant of 30 M was calculated by extrapolation of the curve.   
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2.6 Conclusions and outlook 
In summary, six new prodrugs of Curcumin, based on a carbamoylic linkage with three different 
amino acids, were synthesized. The carbamoylic linkage was chosen in order to enhance hydrolytic 
stability of the compounds in particular at low pH values. The optimized synthetic routes proved to 
be robust and all derivatives were fully characterized by proton and carbon NMR and mass 
spectrometric analyses. 
The stability of the new prodrugs and of Curcumin itself in aqueous media was studied using 
different experimental approaches: UPLC, HPLC/MS, UV-Vis spectroscopy and 1H-NMR. However, 
the study of these processes and systems was severely hindered by the solubility of the new 
Curcumin prodrugs in aqueous media which is rather poor, either under acidic or near neutral pH 
conditions. Compounds 1a-c and 2a-c proved to be more stable in acidic solutions as expected 
based on the known reactivity of the N-monosubstituted carbamoylic linkage. In solutions at pH 
6.8 (as found in the intestine), some degradation was observed. The stability of the new 
derivatives against hydrolysis was also studied by 1H-NMR spectroscopy in water-DMSO-d6 
solutions. No degradation was observed in these aqueous media over three hours. 
Preliminary pharmacokinetic experiments proved that the disubstituted leucine carbamoyl 
derivative of Curcumin is capable of improving the bioavailability of the parent phenol in mice 
model.  
Binding affinity toward plasma proteins was also tested for all derivatives. Fluorimetric binding 
assays to human serum albumin (HSA) showed that all the new derivatives, except for the mono-
leucine prodrug 1a, have higher affinity for HAS than Curcumin itself.  
From these combined data a good distribution in the blood stream and high stability against 
hepatic enzymes can be expected for the new derivatives developed with this thesis, in particular 
for the mono functionalized compounds, which make these compounds potential candidates as 
Curcumin prodrugs. Pharmacokinetic studies for all the other synthesized derivatives are currently 
in progress.  
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2.7. Experimental section  
2.7.1. Materials and methods  
Curcumin was purchased from TCI Europe, amino acids were purchased from Iris Biotech. 
(Marktredwitz, Germany). Other starting materials and reagents were purchased from 
SigmaAldrich (Milan, Italy), Fluka (Milan, Italy), Merck-Novabiochem (Milan, Italy), Acros Organics 
(Milan, Italy), Carlo Erba (Milan, Italy), and were used as received. TLC analyses were performed 
on silica gel supported on plastic (MachereyNagel Polygram®SIL G/UV254, silica thickness 0.2 mm, 
Duren, Germany) and visualized by UV detection. Flash chromatography was performed on silica 
gel (Macherey-Nagel 60, 230–400 mesh, 0.063–0.040 mm) under air pressure. Solvents were 
analytical or synthesis grade and were used without further purification. 1H-NMR and 13C-NMR 
spectra were recorded on a Bruker AVIII spectrometer operating at 300 MHz or on a Bruker 
AVII500 spectrometer operating at 500 MHz. Chemical shifts (δ) are given in ppm relative to the 
signal of the residual undeuterated solvent peak. UPLC-UV analyses were performed with an 
Agilent 1290 Infinity LC System (Agilent Technologies, Milan, Italy), equipped with, a diode array 
detector (190–500 nm) and a reverse phase column (Zorbax RRHD Eclipse Plus C18, 1.8 µm, 50 x 
2.1 mm i.d.; Agilent Technologies). Solvents A and B were water containing 0.1% formic acid and 
acetonitrile, respectively. HPLC/ESI-MS analyses were performed on a 1100 Series Agilent 
Technologies (Milan, Italy) system, equipped with binary pump (G1312A) and reverse phase 
column (Phenomenex Kinetec C-18 2.6 µm 2.1 x 50 mm) a triple quadrupole mass spectrometer 
detector (Varian 320-MS). Solvents A and B were water containing 2% formic acid and acetonitrile, 
respectively. MSD SL Trap mass spectrometer (G2445D SL) with ESI source. ESI-MS positive spectra 
of reaction intermediates and final purified products were obtained from solutions in acetonitrile, 
eluting with Acetonitrile containing 0.1% formic acid. 
 
 
UV Analysis. Samples (500 ul) were analyzed on a Cary 300 UV-Vis spectrophotometer using a 
quartz cell with optical pathlength of 10 mm. All spectra were collected in a specific range of 
wavelength from 300 to 700 nm. For each compound different concentrations (5, 10, 15, 20, 25, 
30 uM) were analyzed in order to acquire a calibration curve. 
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Fluorescence analysis. Fluorescence emission spectra were recorded at 37°C on a Perkin-Elmer LS-
55 spectrofluorimeter. Each compound was dissolved in Ethanol (1mL) to obtain a solution 1mM. 
Human Serum Albumin (HSA) was dissolved in PBS (pH:7.4) to obtain a solution 3uM.  Aliquots 
(1uL) of a specific compound were added to the albumin solution into quartz cells and spectra 
were acquired. All spectra were collected in a specific range of wavelength between 300 and 450 
nm.  
Quartz cells with an optical pathlenght of 10 mm were used for measurement of both 
fluorescence emission and UV-Vis absorption spectra. 
 
 
Hydrolysis Reactions. The chemical stability of all new compounds was tested in aqueous media 
approximating gastric (0.1 N HCl, NormaFix) and intestinal (0.1 M PBS buffer, pH 6.8) pH values. A 
5 µM solution of the compound was prepared from a 5 mM stock solution in DMSO, and 
incubated at 37°C for 24 hours; aliquots of 1 µL were sampled at regular time intervals and 
analyzed by UPLC. The gradient for solvent B is: 10% (0.5 min) then from 80 to 100% in 8 min. Flow 
rate: 0.6 mL/min. The eluate was preferentially monitored at 286, 320 and 425 nm (corresponding 
to absorbance maxima of the internal standard, and curcumin, respectively). The column 
compartment was maintained at 20°C. 
 
 
Pharmacokinetics in blood. Rats of weight between 20 and 25 g were treated via “gavage” with 
suspension of each compound (50 mg/Kg). Samples were prepared suspending each compound in 
water and stirring suspension for 20 minutes. After oral administration, blood sample were 
sampled after 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours and 6 hours. All blood 
samples were collected in heparinised analysis tubes and treated as follows.  
 
 
Blood Sample Treatment and Analysis. Aliquots (200 L) of whole blood were taken at specific 
intervals (5, 10, 30 minutes and 1, 2, 4, 6 hours) and diluted with methanol (200 L) to precipitate 
proteins. Benzanilide (100 L of 220.8 g/mL solution) was added as internal standard. Each 
sample was vortexed, centrifuged (10 minutes, 13000 rpm) and the supernatant was collected, 
concentrated under vacuum and dissolved in methanol (50 L). Then the resulting mixture was 
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analyzed by UPLC injecting 10 L in a C18 Phenomenex 2.6 m 2.1 x 50 mm column and using as 
eluent a gradient of Acetronitrile/H2O +2% of HCOOH from 10% to 95% ACN in 9 minutes. 
 
 
2.7.2 Synthesis and analytical data of compounds 1a-c 
General procedure for the synthesis of protected amino acidic monosubstituted Curcumin [Curc-
m-AAtBuO]:  
Amino acid tert-butyl ester hydrochloride (1 eq.) and 4-(dimethylamino)pyridine (1.5 eq.) were 
dissolved in DCM (5mL). The mixture was cooled at 0°C and a solution of bis(4-nitrophenyl) 
carbonate (0.27 mmol, 1 eq.) in DCM was added dropwise. After stirring for 4 hours at room 
temperature a fresh solution of Curcumin (0.27 mmol, 1 eq.) and 4-(dimethylamino)pyridine (0.27 
mmol, 1 eq.) in THF was added dropwise and mixture was stirred at 50°C overnight. Reaction 
mixture was then washed with HCl 0.1 N (2x10 mL) and the aqueous layer extracted from EtOAc 
(3x20 mL). Organic layer was dried over Na2SO4 and concentrated under vacuum.  The resulting 
solid was purified by flash chromatography  to obtain the desired compound as an orange solid.  
 
 
tert-butyl((4-((1E,3Z,6E)-3-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-5-oxohepta-1,3,6-trien-1-yl)-
2-methoxyphenoxy)carbonyl)-L-leucinate [Curc-m-LeutBuO]: Flash chromatography conditions: 
SiO2, eluent Petroleum ether/ethyl acetate 6:4.  Yield: 82%.  
1H-NMR (300 MHz, d6 -DMSO)  
9.67 (s, 1H), 8.12 (d, J=8.0 Hz,  1H) 7.60 (d, J = 15.7 Hz, 2H), 7.40 (d, J = 38.1 Hz, 2H), 7.22 (dd, J = 
33.7, 8.0 Hz, 2H), 7.14 – 6.87 (m, 2H), 6.81 (dd, J = 18.5, 12.0 Hz, 2H), 6.13 (s, 1H), 3.96 (m, 1H), 
3.84 (s, 3H), 3.83 (s, 3H) 1.81 – 1.68 (m, 1H), 1.67 – 1.48 (m, 2H), 0.92 (dd, J = 11.3, 6.5 Hz, 6H) 
ppm. 13C NMR (75 MHz, DMSO-d6) δ= 184.71, 181.60, 171.60, 153.79, 151.79, 149.57, 148.02, 
141.45, 139.15, 133.12, 126.26, 124.26, 123.46, 123.27, 121.14, 115.74, 112.04, 111.46, 101.26, 
80.55, 55.84, 55.69, 53.20, 27.60, 24.33, 22.72, 21.26, 14.04 ppm. ESI/MS m/z [M+H+]: 582 
 
 
tert-butyl((4-((1E,3Z,6E)-3-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-5-oxohepta-1,3,6-trien-1-yl)-
2-methoxyphenoxy)carbonyl)-L-isoleucinate [Curc-m-IletBuO]: Flash chromatography conditions: 
SiO2, eluent Petroleum ether/ethyl acetate 6:4.  Yield: 89%.  
1H NMR (300 MHz, DMSO-d6) δ=  9.67 
(s, 1H), 8.07 (d, J = 8.3 Hz, 1H), 7.60 (d, J = 15.7 Hz, 2H), 7.40 (d, J = 39.6 Hz, 2H), 7.23 (dd, J = 34.2, 
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8.4 Hz, 2H), 7.17 – 6.86 (m, 2H), 6.88 – 6.72 (m, 2H), 6.13 (s, 1H), 3.89 (m, 1H), 3.84 (s, 3H), 3.83 (s, 
3H), 1.90 – 1.73 (m, 1H), 1.43 (s, 9H), 1.28 (m, 2H), 0.89 (m, J = 7.1 Hz, 6H) ppm. 13C NMR (75 MHz, 
DMSO-d6) δ 184.71, 181.59, 170.47, 153.97, 151.79, 149.54, 148.00, 141.44, 139.16, 133.12, 
126.23, 124.26, 123.48, 123.29, 121.14, 115.72, 112.03, 111.46, 101.23, 80.64, 59.35, 55.87, 55.69, 
36.40, 27.65, 24.81, 15.34, 11.17 ppm. ESI/MS m/z [M+H+]:582 
 
tert-butyl((4-((1E,3Z,6E)-3-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-5-oxohepta-1,3,6-trien-1-yl)-
2-methoxyphenoxy)carbonyl)-L-valinate [Curc-m-ValetBuO]: Flash chromatography conditions: 
SiO2, eluent Petroleum ether/ethyl acetate 6:4.  Yield: 91%. 
1H NMR (300 MHz, DMSO-d6) δ 9.70 (s, 
1H), 8.09 (d, J = 8.4 Hz, 1H), 7.60 (dd, J = 15.8, 2.1 Hz, 2H), 7.49 – 7.33 (m, 2H), 7.32 – 7.15 (m, 2H), 
7.15 – 6.90 (m, 2H), 6.86 – 6.76 (m, 2H), 3.85 (s, 3H), 3.83 (s, 3H), 3.81 (m, 1H), 2.08 (dt, J = 12.4, 
6.7 Hz, 2H), 1.44 (s, 9H), 0.95 (d, J = 6.8 Hz, 6H) ppm. 13C NMR (76 MHz, DMSO-d6) δ 184.72, 
181.59, 154.08, 151.80, 149.53, 148.00, 141.42, 139.17, 133.12, 126.22, 124.26, 123.50, 123.31, 
121.23, 121.13, 115.70, 112.03, 111.43, 101.24, 80.64, 60.43, 55.88, 55.69, 29.96, 27.66, 18.89, 
18.03 ppm. ESI/MS m/z [M+H+]: 568 
 
 
General procedure for the synthesis of Amino acidic monosubstituted Curcumin [1a-c]: 
Curc-m-AAtBuO (0.21 mmol, 1eq.) was dissolved in DCM and cooled to 0°C. TFA (8.64 mmol, 40 
eq.) was added dropwise then 1% of TIPS was added. Reaction was stirred for 5 hours at room 
temperature. DCM was evaporated under vacuum and TFA was diluted with toluene and 
evaporated under vacuum. The resulting solid was purified by flash chromatography  to afford the 
final product.  
 
 
((4-((1E,3Z,6E)-3-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-5-oxohepta-1,3,6-trien-1-yl)-2-
methoxyphenoxy)carbonyl)-L-leucine [1a]: ]: Flash chromatography conditions: SiO2, eluent 
Dichloromethane/Acetone/Acetic acid  95:5:0.2.  Yield: 90%.  1H-NMR (300 MHz, d6 -
DMSO)9.67 (s, 1H), 8.09 (d, J = 8.2 Hz, 1H), 7.59 (d, J = 16.0 Hz, 2H), 7.42 (m, 2H), 7.31 – 7.14 
(m, 2H), 7.15 – 6.88 (m, 2H), 6.87 – 6.72 (m, 2H), 6.13 (m, 1H), 4.02 (s, 1H), 3.84 (s, 3H), 3.82 (s, 
3H), 2.75 (dd, J = 21.4, 7.0 Hz, 1H), 1.66 – 1.48 (m, 2H), 0.92 (dd, J = 9.8, 6.6 Hz, 6H) ppm.13C NMR 
(75 MHz, DMSO-d6) δ 184.72, 181.63, 173.94, 171.98, 153.82, 151.76, 149.54, 148.01, 141.46, 
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139.21, 133.05, 126.24, 124.25, 123.43, 123.32, 121.16, 115.72, 112.01, 111.46, 101.22, 55.87, 
55.71, 52.40, 24.32, 22.88, 21.14, 21.02 ppm. ESI/MS m/z [M+H+]: 526 
 
 
((4-((1E,3Z,6E)-3-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-5-oxohepta-1,3,6-trien-1-yl)-2-
methoxyphenoxy)carbonyl)-L-isoleucine [1b]: Flash chromatography conditions: SiO2, eluent 
Dichloromethane/Acetone/Acetic acid  95:5:0.2.  Yield: 85%.  1H NMR (300 MHz, DMSO-d6) δ ),  , 
9.66 (s, 1H), 8.04 (d, J = 8.6 Hz, 2H), ), 7.60 (d, J = 15.3 Hz, 2H), 7.40 (d, J = 40  Hz, 2H), 7.23 (dd, J = 
34.2, 8.4 Hz, 2H), 7.17 – 6.86 (m, 2H), 6.88 – 6.72 (m, 2H), 6.13 (s, 1H), 3.94 (m, 1H), 3.84 (s, 3H), 
3.83 (s, 3H), 1.55-1.37(m, 1H), 1.36-1.20 (m, 2H),  0.89 (m, J = 6.9 Hz, 6H) ppm. 13C NMR (75 MHz, 
DMSO-d6) δ 184.70, 181.61, 172.87, 171.97, 154.03, 151.79, 149.53, 148.01, 141.46, 139.19, 
133.07, 126.23, 124.25, 123.48, 123.31, 121.15, 115.72, 112.00, 111.45, 101.22, 58.81, 55.90, 
55.71, 36.22, 24.59, 21.02, 15.52, 11.20 ppm. ESI/MS m/z [M+H+]: 526 
 
 
((4-((1E,3Z,6E)-3-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-5-oxohepta-1,3,6-trien-1-yl)-2-
methoxyphenoxy)carbonyl)-L-valine [1c]: Flash chromatography conditions: SiO2, eluent 
Dichloromethane/Acetone/Acetic acid  95:5:0.2.  Yield: 95%.  1H NMR (300 MHz, DMSO-d6) δ 9.66 
(s, 1H), 8.03 (d, J = 8.6 Hz, 1H), 7.59 (dd, J = 15.8, 3.1 Hz, 2H), 7.40 (d, J = 39.6 Hz, 2H), 7.31 – 7.14 
(m, 2H), 7.14 – 6.88 (m, 2H), 6.86 – 6.75 (m, 2H),  6.13 (s, 1H), 3.91 (dd, J = 8.7, 6.1 Hz, 1H), 3.84 (s, 
3H), 3.83 (s, 3H), 2.12 (m, 1H), 0.95 (dd, J = 6.8, 2.9 Hz, 6H) ppm. 13C NMR (75 MHz, DMSO-d6) δ 
184.70, 181.59, 170.48, 154.08, 151.80, 149.53, 148.00, 141.44, 139.16, 133.12, 126.22, 124.25, 
123.49, 123.29, 121.13, 115.71, 112.04, 111.45, 101.22, 80.63, 60.43, 55.87, 55.69, 29.96, 27.65, 
18.87, 18.02 ppm. ESI/MS m/z [M+H+]: 512 
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2.7.3 Synthesis and analytical data of compounds 2a-c 
General procedure for the synthesis of protected Amino acidic di-substituted Curcumin [Curc-d-
AAtBuO]:  
A solution amino acid tert-butyl ester hydrochloride (2 eq.) and 4-(dimethylamino)pyridine (2.5 
eq.) in DCM was added dropwise to a cold (0°C) solution of bis(4-nitrophenyl) carbonate (2.5 eq.) 
in DCM (5mL). After stirring for 4 hours at room temperature a fresh solution of Curcumin (1 eq.) 
and 4-(dimethylamino)pyridine (2.5 eq.) in DCM was added dropwise and mixture was stirred at 
50°C overnight. Solvent was evaporated under vacuum, the residue dissolved in EtOAc and 
washed with HCl 0.1 N (2x10 mL). The combined aqueous layer was extracted from EtOAc (3x20 
mL). Organic layer was dried over Na2SO4 and concentrated under vacuum.  The resulting solid 
was purified by flash chromatography to obtain a yellow solid.  
 
 
di-tert-butyl-2,2'-((((((1E,3Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-1,7-diyl)bis(2-methoxy-4,1-
phenylene))bis(oxy))bis(carbonyl))bis(azanediyl))(2S,2'S)-bis(4-methylpentanoate) [Curc-di-
LeutBuO]: 
Flash chromatography conditions: SiO2, eluent petroleum ether/Ethyl acetate 7:3.  Yield: 73%. 
1H 
NMR (300 MHz, DMSO-d6) δ 8.13 (d, J = 8.0 Hz, 2H), 7.65 (d, J = 15.8 Hz, 2H), 7.48 (s, 2H), 7.30 (d, J 
= 7.6 Hz, 2H), 7.13 (d, J = 7.9 Hz, 2H), 6.96 (d, J = 15.6 Hz, 2H), 6.20 (s, 1H), 4.02 – 3.91 (m, 2H), 3.83 
(s, 6H), 1.73 (m, 2H), 1.66 – 1.48 (m, 4H), 1.42 (s, 18H), 0.92 (dd, J = 11.8, 6.5 Hz, 12H) ppm. 13C 
NMR (76 MHz, DMSO) δ 183.20, 170.30, 153.75, 151.78, 141.56, 139.61, 132.99, 124.30, 123.49, 
121.38, 112.11, 101.58, 80.57, 55.88, 53.16, 27.61, 24.30, 22.74, 21.26 ppm. ESI/MS m/z 
[M+H+]:795 
 
 
di-tert-butyl-2,2'-((((((1E,3Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-1,7-diyl)bis(2-methoxy-4,1-
phenylene))bis(oxy))bis(carbonyl))bis(azanediyl))(2S,2'S,3S,3'S)-bis(3-methylpentanoate) [Curc-
di-IletBuO]: Flash chromatography conditions: SiO2, eluent petroleum ether/Ethyl acetate 7:3.  
Yield: 71%. 1H NMR (300 MHz, DMSO-d6) δ 8.08 (d, J = 8.6 Hz, 2H), 7.64 (d, J = 16.0 Hz, 2H), 7.48 (s, 
2H), 7.30 (d, J = 7.9 Hz, 2H), 7.13 (d, J = 8.0 Hz, 2H), 6.97 (d, J = 15.8 Hz, 2H), 6.20 (s, 1H), 3.88 (m, 
2H), 3.83 (s, 6H), 1.82 (m, 2H), 1.46 (m, 4H), 1.43 (s, 18H), 0.89 (dd, J = 13.8, 6.9 Hz, 12H) ppm. 13C 
NMR (76 MHz, DMSO) δ 183.20, 170.48, 153.97, 151.82, 141.59, 139.92, 133.02, 124.30, 123.51, 
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121.38, 112.11, 101.61, 59.36, 55.87, 36.43, 27.65, 24.83, 20.71, 15.35, 11.18 ppm. ESI/MS m/z 
[M+H+]: 795 
 
 
di-tert-butyl-2,2'-((((((1E,3Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-1,7-diyl)bis(2-methoxy-4,1-
phenylene))bis(oxy))bis(carbonyl))bis(azanediyl))(2S,2'S)-bis(3-methylbutanoate) [Curc-di-
ValetBuO]: Flash chromatography conditions: SiO2, eluent petroleum ether/Ethyl acetate 7:3.  
Yield: 80%. 1H NMR (300 MHz, DMSO-d6) δ 8.08 (d, J = 7.5 Hz, 2H), 7.65 (d, J = 15.8 Hz, 2H), 7.48 (s, 
2H), 7.30 (d, J = 8.1 Hz, 2H), 7.13 (d, J = 8.1 Hz, 2H), 6.95 (d, J = 15.9 Hz, 2H), 6.19 (s, 1H), 3.86 (dd, J 
= 6.1, 4.0 Hz, 2H), 3.83 (s, 6H), 2.10 (m, 2H), 1.44 (s, 18H), 0.96 (d, J = 6.8 Hz, 12H) ppm. 13C NMR 
(75 MHz, DMSO-d6) δ 183.21, 170.52, 154.11, 151.86, 141.62, 139.91, 133.05, 124.32, 123.52, 
121.36, 112.14, 101.62, 80.65, 60.46, 55.88, 30.02, 27.66, 18.89, 18.02 ppm. ESI/MS m/z [M+H+]: 
767 
 
 
General procedure for the synthesis of Amino acidic disubstituted Curcumin [2a-c]: 
Curc-d-AAtBuO, (1eq.) was dissolved in DCM (40 eq.) and cooled to 0°C. TFA (40 eq.) was added 
dropwise then 1% of TIPS was added. Reaction was stirred for 5 hours at room temperature. DCM 
was evaporated under vacuum and TFA was diluted with toluene and evaporated under vacuum. 
The resulting solid was purified by flash chromatography to afford the product. 
 
 
(2S,2'S)-2,2'-((((((1E,3Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-1,7-diyl)bis(2-methoxy-4,1-
phenylene))bis(oxy))bis(carbonyl))bis(azanediyl))bis(4-methylpentanoic acid) [2a]: Flash 
chromatography conditions: SiO2, eluent Dichloromethane/Acetone/Acetic acid  95:5:0.2. Yield: 
90%.  1H NMR (300 MHz, DMSO-d6) δ 8.10 (d, J = 8.1 Hz, 2H), 7.64 (d, J = 16.0 Hz, 2H), 7.48 (s, 2H), 
7.30 (d, J = 8.3 Hz, 2H), 7.13 (d, J = 8.1 Hz, 2H), 6.96 (d, J = 16.0 Hz, 2H), 6.20 (s, 1H), 4.04 (m, 2H), 
3.83 (s, 6H), 1.71 (d, 2H), 1.66 – 1.44 (m, 4H), 0.92 (dd, J = 9.3, 6.7 Hz, 12H) ppm. ESI/MS m/z 
[M+H+]: 685 
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(2S,2'S,3S,3'S)-2,2'-((((((1E,3Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-1,7-diyl)bis(2-methoxy-4,1-
phenylene))bis(oxy))bis(carbonyl))bis(azanediyl))bis(3-methylpentanoic acid) [2b]: Flash 
chromatography conditions: SiO2, eluent Dichloromethane/Acetone/Acetic acid  95:5:0.2.  Yield: 
85%. 1H NMR (300 MHz, DMSO-d6) δ 8.05 (d, J = 8.7 Hz, 2H), 7.64 (d, J = 16.0 Hz, 2H), 7.48 (s, 2H), 
7.30 (d, J = 8.0 Hz, 2H), 7.13 (d, J = 8.1 Hz, 2H), 6.96 (d, J = 15.9 Hz, 2H), 3.94 (dd, J = 8.3, 6.4 Hz, 
4H), 3.83 (s, 6H), 1.85 (m, 2H), 1.54 – 1.20 (m, 4H), 0.97 – 0.81 (m, 12H) ppm. 13C NMR (76 MHz, 
DMSO) δ 183.23, 172.91, 172.01, 154.04, 151.82, 141.66, 139.97, 132.99, 124.30, 123.53, 121.41, 
112.10, 101.61, 58.83, 55.92, 36.24, 24.61, 21.05, 15.54, 11.22 ppm. ESI/MS [M+H+]: 685 
 
 
(2S,2'S)-2,2'-((((((1E,3Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-1,7-diyl)bis(2-methoxy-4,1-
phenylene))bis(oxy))bis(carbonyl))bis(azanediyl))bis(3-methylbutanoic acid) [2c]: Flash 
chromatography conditions: SiO2, eluent Dichloromethane/Acetone/Acetic acid  95:5:0.2.  Yield: 
95%.  1H NMR (300 MHz, DMSO-d6) δ 8.04 (d, J = 8.7 Hz, 2H), 7.64 (d, J = 15.8 Hz, 2H), 7.48 (s, 2H), 
7.30 (d, J = 8.1 Hz, 2H), 7.13 (d, J = 8.1 Hz, 2H), 6.96 (d, J = 16.0 Hz, 2H), 6.20 (s, 1H), 3.91 (dd, J = 
8.6, 6.0 Hz, 2H), 3.83 (s, 6H), 2.12 (dq, J = 13.2, 6.7 Hz, 2H), 0.95 (dd, J = 6.8, 2.8 Hz, 12H) ppm. 13C 
NMR (75 MHz, DMSO-d6) δ 183.33, 172.81, 154.11, 151.96, 141.45, 139.94, 132.95, 124.12, 
123.50, 121.38, 112.09, 101.25, 59.75, 55.90, 29.76, 19.06, 17.93 ppm. ESI/MS m/z [M+H+]: 657 
 
 
 
 
 
 
 
 
 
 
 
 
 
 61 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
New polymeric prodrug systems 
of Curcumin 
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3.1 Polymer therapeutics  
 
The use of polymers in pharmaceutical field has attracted major interest in recent years, such 
derivatives are generally addressed as “polymer therapeutics”.122-125 In particular, new complex 
polymer-based systems were developed, and new biomaterials were investigated in order to 
create new drug delivery systems.126-131 According to Ringsdorf’s model the composition of  
polymeric prodrugs is characterized by three different parts: 
- a polymeric backbone; 
- a drug, with poor water solubility and instability at physiological pH preferably; 
-  a spacer, which is able to control the rate of drug release.132-134 
In more complex systems, targeting groups called “homing devices”, that increase the selectivity 
of drug delivery, and imaging agents, for diagnostic purposes can also be employed.135  
Polymer therapeutics involves several types of systems: polimer-drug conjugates, polymer-protein 
conjugates, polymeric micelles, aggregates and nanoparticles.123,130,136-151 
These latter correspond to the most largely employed systems in drug delivery because of their 
potential to extend towards more complex systems and tuning their properties. Furthermore, 
these systems are characterized by high thermodynamic stability, low critical micellar 
concentration (CMC) values (10-8-10-2 mol L-1) that allow to keep their assembled conformations 
upon dilution.152 Working with polymers offers several advantages, in particular the 
straightforward synthesis, the water solubility, and the possibility to tailor specific 
architectures.153-154 Furthermore polymers usually show low toxicity and weak protein 
interactions, and their conjugation with hydrophobic drugs promotes an increase in water 
solubility, protection by metabolic enzymes and an enhancement of drug bioavailability.135,155-157  
Several random coil polymers were employed in polymer therapeutics, but the most commonly 
used are poly-glutamic acid (PGA), poly-ethylene glycol (PEG), poly-hydroxypropyl methacrilate 
(HPMA), poly-vinylpyrrolidone (PVP) and poly-L-lysine (PLL).158 Other commonly employed 
macromolecules include chitosan, dextran, and poly-2-alkyl-2-oxazolines (POXA).159,160 In 
particular, poly-2-alkyl-2-oxazolines (polyoxazolines) have shown good biocompatibility and 
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stability over time, thus becoming the object of several studies for the synthesis of new 
pharmaceutical systems.159,161-163  
 
3.2 Polyoxazolines  
Polyoxazolines are a family of polymers isomeric to  polypeptides or poly-acrylamides bearing a 
primary amide moiety [Fig.25]. These macromolecules are characterized by a high chemical 
stability, a lower critical solution temperature (LCST) , and they are generally  soluble in water and 
in common organic solvents.164,165 
 
Figure 25. Common structure of poly-oxazolines 
 
 
 
 
The use of POXA is advantageous under many points of view. In particular the straightforward 
synthesis via living cationic ring opening polymerization (CROP) which offers wide possibilities to 
tune the architecture of the polymer.166 As all other polymerization reactions, it is divided into 
three steps: initiation, prolongation and termination167 [Sch.2]. Many studies were carried out to 
investigate the possibility to modulate the structure and the architecture of these polymers by the 
choice of initiating and terminating compounds.168-170 Initiation step involves activation of the 2-
oxazoline ring by an electrophilic compound generating a 2-oxazolinium cation, alkyl triflate or 
tosylate proved to be the best for this purpose.171-175 Halides, silicates and zirconium-based 
compounds can also be used as initiators. In order to allow for further functionalization of the 
polymer via click chemistry, alkene and alkyne based initiators were also considered.168 
In the propagation step, the activated 2-oxazolonium can react in position 4 with another 
oxazoline molecule alkylating the nitrogen and transferring the positive charge, which can then 
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further react with another monomer. The propagation reaction can proceed as long as monomer 
is present in solution and the cationic head group of the growing chain is not quenched by a 
nucleophile. For this reason the polymerization is called “living”. This feature allows for a high 
control over the final molecular weight of the polymer as well as for the synthesis of block-
copolymers.176 
Terminating agents are represented by nucleophiles able to stop the living cationic process by 
quenching the cation reactive species in 5’ position. Water, alcohols and amines can be identified 
as the most used terminators. Azides also showed good ability to stop the polymerization.174 For 
this reason, nucleophilic groups, such as hydroxyl (OH), mercapto (SH) and amino (NH2), on the 
initiator are tolerated but need to be protected in order to reduce potential interferences with the 
polymerization process.175 
Furthermore it has been shown that the chain end-group is the main responsible of antimicrobial 
activity and hemocompatibility of these polymers.176,177 
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Scheme 2. The three steps of POXA synthesis reaction 
 
 
 
 
 
 
 
In particular, poly-2-alkyl-2-oxazolines (POXA) emerged as suitable replacements for PEGs, virtually 
in all the biomaterials-related applications, thanks to their biocompatibility coupled to their 
distinctive chemical stability.178-180  
However, PEGs and their derivatives undergo oxidative and enzymatic degradation in physiological 
media, originating toxic compounds and limiting their application in drug formulations.181,182 In 
addition, PEG therapeutics are known to show accelerated blood clearance (ABC) due to the 
formation of anti-PEG antibodies by the immune system after the initial treatment.183 Moreover 
there has been an increasing evidence of the formation of anti-PEG antibodies also in individuals 
who have never been exposed to PEGylated drugs, presumably due to its extensive use in 
cosmetics, household, and hygiene products.184,185 
Conjugates with proteins as well as with drugs generally showed a similar behavior between POXA 
and PEG. Hoogemboom, Veronese and coworkers reported that the conjugation of PEtOXA to 
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Trypsin does not affect the enzymatic activity towards low molecular substrates.178 Comparison 
with the corresponding PEG derivative showed similar protein repelling properties. Furthermore 
conjugation of PEtOXA with cytosine arabinose demonstrated an equivalent behavior towards 
cytidine deaminase inhibition as for the corresponding PEG derivative.178 Textor et al. pioneered 
the use of PMOXAs for the preparation of protein repellent surfaces, providing evidence for a 
similar antifouling activity of surface-grafted PMOXA compared to PEG.179,180  
In particular poly-2-methyl-2-oxazolines (PMOXA) and poly-2-ethyl-2-oxazolines (PEtOXA) 
represent the most commonly used PAOXAs for drug formulations due to their high hydrophilicity, 
the absence of in vivo toxicity, and rapid blood clearance via the kidneys.163-165,186 In particular 
Veronese and coworkers showed that the lipophilicity of PMOXA is significantly lower than 
PEtOXA, and PPrOXA.165 Moreover Jordan et al. studied the biodistribution and excretion of 
radiolabeled PMOXA of different molecular weight showing no significant accumulation in tissues 
and only 2% of the inoculated amount being still present in the blood after 30 min.186 
Direct conjugation of POXAs with drugs to obtain polymer-therapeutics is not extensively studied 
and only few examples are known. Among others cytosine arabinose-PEtOXA conjugate by 
Hoogenboom, and irinotecan and rotigotine conjugates that showed comparable properties with 
the corresponding PEG conjugates.158,178-186  
Inspired by the attractive features of PMOXA we present the first example of PMOXA-based 
carbamoyl prodrugs of curcumin. Such systems are capable to self-assemble in water to form 
curcumin-PMOXA core-shell nanoparticles. 
The influence of PMOXA chain length on the size and the stability of the particles, and the release 
rate of curcumin was systematically investigated.  
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3.3 Synthesis and Self-Assembly of Curcumin-
PMOXA Conjugates  
Amino-end-functional PMOXAs of different lengths were firstly synthesized by cationic ring 
opening polymerization (CROP).  
CROPs of 2-methyl-2-oxazoline (MOXA) were initiated by methyl-trifluoromethansulfonate 
(MeOTf) and terminated by addition of ammonia, yielding PMOXA-NH2 presenting five different 
molar masses, as determined by varying the initiator/monomer feed ratio.  PMOXA-NH2 
presenting average chain lengths of 10, 20, 30, 50 and 100 monomer units (as estimated by H-
NMR) were named  PMOXA10, PMOXA20, PMOXA30, PMOXA50 and PMOXA100, respectively (3a-
e). The conjugation of the polymers to one hydroxyl function of Curcumin was carried out using 
the  same one pot synthetic procedure previously described in chapter  2. In particular, amino 
terminal groups were activated by reaction with bis(4-nitrophenyl) carbonate. The resulting active 
urethane was reacted with Curcumin in a 1:1 stoichiometry in order to ensure mono 
functionalization [Fig. 26]. Five derivatives were synthesized according to this procedure:  
 
 Curcumin-PMOXA10 (4a) 
 Curcumin-PMOXA20 (4b) 
 Curcumin-PMOXA30 (4c) 
 Curcumin-PMOXA50 (4d) 
 Curcumin-PMOXA100(4e) 
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Figure 26. a) Synthesis of amino-terminated PMOXA (1) and conjugation with Curcumin via 
carbamoyl linkage (2). b) Nanoparticle formation by self-assembly of the Curcumin-PMOXA 
conjugates in water. 
 
 
 
 
 
 
A common 1H-NMR of a PMOXA is characterized by a specific pattern of signals as shown in figure 
27 below. In particular, the signal related to the protons (N-CH3) of the terminal methyl group 
between 2.9 and 3.1 ppm appears splitted because of the attachment to an amide backbone than 
is subjected to cis/ trans isomerism. This specific signal  was used to normalize the number of 
protons in  the spectrum.187 
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Figure 27.  1H-NMR (300 MHz, D2O)  spectrum of PMOXA30. Signal pattern of terminal methyl 
group (red) is expanded. 
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The compounds were purified by dialysis, and characterized by 1H NMR. As an example 1H-NMR 
spectrum of 4c were reported in Figure 28. 
In the 1H-NMR spectrum, aromatic protons showed a characteristic signal pattern due to the loss 
of symmetry by molecule. The singlet at 9.8 ppm was identified as phenolic proton of Curcumin as 
evidence of mono substitution. Between 2 and 4 ppm another pattern of signals related to the 
polymeric backbone was identified. 
 
 
 
Figure 28. 1H-NMR (300 MHz,  DMSO-d6) spectrum of Curcumin-PMOXA30 
 
 
 
  
Polymer Signals 
Characteristic signal 
pattern of mono-
substituted Curcumin 
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Curcumin-PMOXA micelles were subsequently prepared by dissolving each polymer conjugate in a 
mixture of acetonitrile:dimethylsulfoxide  (9:1) and dialyzing it against water for 24 hours [Fig. 
26b]. The critical micellar concentration (CMC) was later determined according to the literature 
procedure using pyrene as fluorescence probe sensitive to the hydrophobicity of the 
environment.188  
Pyrene’s fluorescence is indeed very sensitive to changes in polarity of the chemical environment. 
Thus when pyrene  is trapped inside the micelles its fluorescence is quenched and the relative 
ratio of intensity of the peaks at 373 and 383 nm decreases. The critical micellar concentration can 
be calculated by interpolation from the plot of the intensity ratio of the peaks at 373 nm and at 
383 nm as a function of concentration [Fig.29b]. 
 
As reported in Table 2, Curcumin-PMOXA20 and Curcumin-PMOXA30 derivatives showed the 
lowest values of CMC indicating the formation of micelles already at µM range of polymer 
concentrations. On the contrary, Curcumin-PMOXA50 and curcumin-PMOXA100 showed very high 
CMC values, presumably due to the long hydrophilic polymer segments which stabilized the 
conjugates in water hindering the self-assembly process into micelles of the molecules. The high 
CMC value observed for Curcumin-PMOXA10 could be related to the short hydrophilic segment 
yielding low water-solubility of this conjugate, which resulted in aggregation and precipitation as 
confirmed by dynamic light scattering (DLS) and transmission electron microscopy (TEM).    
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Figure 29. a) Fluorescence spectra of solutions of 4c at different concentrations. ex: 340 nm; 
[Pyrene]: 1 ppm; b) linear extrapolation of the CMC 
 
 
 
 
 
Table 2. Experimental critical micellar concentration (CMC) values for derivatives CuPMOXA10-
100. 
Compound M.W. (Da) CMC (mol L-1) 
CuPMOXA10 (4a) 1275 1.2x10-4 
CuPMOXA20 (4b) 2094 8.6x10-6 
CuPMOXA30 (4c) 2975 8.6x10-6 
CuPMOXA50 (4d) 4676 3.9x10-4 
CuPMOXA100 (4e) 8925 3.5x10-4 
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3.4 Size and stability of polymeric micelles 
In order to evaluate the size and the morphology of the different Curcumin-PMOXA micelles, DLS 
TEM were employed.  
DLS measurements performed in water highlighted the influence of PMOXA chain length on the 
average size of the formed  micelles. As reported in Figure 30 an average diameter of about 
411±98 nm was recorded for Curcumin-PMOXA10 (4a), and confirmed by TEM micrographs 
[Fig.31]. The large diameter of the micelles originated from this compound was due to the 
relatively short PMOXA segment, which was not sufficient to balance the hydrophobic interactions 
between the Curcumin moieties within the aggregates.  
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Figure 30. Dynamic light scattering (DLS) analysis of micelles formed by derivatives a) 
CuPMOXA10, b) CuPMOXA20, c) CuPMOXA30, d) CuPMOXA50, e) CuPMOXA100. 
 
 
 
 
 
The DLS profiles of the micellar suspensions prepared from Curcumin-PMOXA20 (4b) and 
Curcumin-PMOXA30 (4c) showed similar average diameters for both the samples, with typical 
values around 100 ± 23 and 104 ± 24 nm, respectively. Interestingly, the TEM micrographs 
recorded for 4b showed the presence of larger aggregates than what expected from the DLS 
analysis, with micelles presenting typical diameters over 200 nm [Fig. 31b]. The discrepancy 
between DLS and TEM measurements for this particular sample was probably due to the intrinsic 
instability of the micellar suspensions originated from Curcumin-PMOXA20, as it was subsequently 
demonstrated by the stability studies (vide infra).  
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Figure 31. TEM micrographs of nanoparticles formed in water by a) CuPMOXA10, b) 
CuPMOXA20, c) CuPMOXA30, d) CuPMOXA50, e) CuPMOXA100. Aggregation is visible for 
CuPMOXA10. 
 
 
 
 
 
The micelles formed from 4d and 4e showed average diameters of 43 ± 13 and 32 ± 8 nm, 
respectively, and monodisperse populations, with a good agreement between DLS and TEM 
analyses [Fig.s 30d, 30e, and 31d, 31e]. The smaller diameters recorded for these micellar 
aggregates was ascribed to the relatively long PMOXA segments, which favoured the formation of 
colloidally stable micelles constituted by a limited number of Curcumin-PMOXA conjugates.  
Specifically, the polymeric backbone “crumble” is due to the random coil disposition of the 
polymeric chains. These latter are able to create steric hindrance which influences the density and 
the thickness of the shell [ Fig. 32].  
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Figure 32. a) Micellization process and disposition of polymeric chains of the shell for lower 
chain length derivatives b) micellization process and disposition of polymeric chains of the shell 
for  higher chain length derivatives  
 
 
 
 
 
 
The stability of the different micellar suspensions was subsequently tested by DLS over one month 
of incubation in water at 4 °C.145  Suspensions form Curcumin-PMOXA30, 50 and 100 conjugates 
showed good colloidal stability over the tested time, with diameter values which remain constant 
over 4 weeks. On the contrary, suspensions of Curcumin-PMOXA10 and Curcumin-PMOXA20 
showed a marked variation of average micellar diameter over time. Micelles originated from 
Curcumin-PMOXA10 underwent a very fast aggregation, which was macroscopically mirrored by 
the precipitation of aggregates already after 10 minutes of incubation at 4 °C.  
Conversely, the average diameter recorded for Curcumin-PMOXA20 showed a gradual decrease 
during the tested 4 weeks of incubation at 4°C. This phenomenon could be ascribed to digestive 
ripening, i.e. a progressive variation of the aggregates size in order to reach a thermodynamically 
more favourable state.189-192 In this case, the initially large micelles observed for Curcumin-
PMOXA20 gradually dissolved into a monodispersed micellar population presenting an average 
diameter of 31 ± 2 nm.  This phenomenon was also confirmed by TEM, which showed the 
formation of relevantly smaller micelles after 4 weeks of incubation [Fig. 33b-c]. 
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Figure 33. a) Stability over time of the micellar structures assessed by repeated DLS inspection. 
b) TEM micrograph of CuPMOXA20 at time 0 and c) after 4 weeks, showing shrinking of the self-
assembled structures. 
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3.5 Curcumin Release from Micelles and 
Biocompatibility 
The release of curcumin from the different micellar suspensions was evaluated under physiological 
conditions (PBS solution at pH 7.4 and at 37°C) by UV-Vis spectroscopy, monitoring the decrease in 
the relative absorption of the Curcumin peak at 430 nm during 24 hours, assuming that all the 
released Curcumin precipitates upon hydrolysis.  
As highlighted in Figure 34, the most efficient release of active compound was recorded for 
Curcumin-PMOXA30. Namely, about 70% of the initial Curcumin content in the micelles was 
released within the first 2 hours of incubation, while after 24 hours the released fraction reached 
88%, following a pseudo-first order kinetic.  
  
Figure 34. Release profile of Curcumin (yellow) from 4c (orange) at pH:7.4. Temperature 37°C. 
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All the other conjugates exhibited a slower release kinetics [Fig.36]. About 64% of the Curcumin 
was released from Curcumin-PMOXA10, and 30% from Curcumin-PMOXA20 after 24 hours. The 
faster release of Curcumin-PMOXA10 compared to Curcumin-PMOXA20, being partially due to the 
already observed tendency to precipitate by the former conjugate. For these samples, the release 
kinetics were characterized by an initial, fast release rate of Curcumin followed by a marked 
slowing down at longer incubation times.  This was presumably due to the occurrence of two 
different release mechanisms from the micellar suspensions. One could be ascribed to the 
dissociation of the micelles and another one, presumably taking place after several hours of 
incubation, which was correlated to the hydrolytic cleavage of carbamoyl bond between curcumin 
and the polymer.193,194 
The release of Curcumin further decreased by increasing the length of the PMOXA segments 
within the conjugates (and thus by decreasing the average diameter of the micelles). In fact, the 
release of 16% and 8% of Curcumin was recorded for micellar suspensions of Curcumin-PMOXA50 
and Curcumin-PMOXA100, respectively. In these two cases, the high stability and relatively small 
size of the formed micelles hindered the dissociation of Curcumin by hydrolysis and/or the 
dissolution of the entire micelles [Fig.35]. 
 
 
 
Figure 35. Illustration of the two supposed mechanism involved in drug release from micelles 
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Figure 36. Curcumin release profiles of the CuPMOXA conjugates. Releasing was tested at a 
concentration of the conjugates of 10-3 M, under simulated physiological conditions: PBS buffer pH 
7.4 and 37°C. 
 
 
 
 
 
Cell viability tests were performed in order to assess the biocompatibility and cytotoxicity of the 
different CuPMOXA conjugates [Fig.37].  In particular, macrophages  (raw 264.7 cell line) were 
incubated in cell culture medium containing different concentrations of the  curcumin-conjugates 
for 24h and the MTS assay showed cell viability above 85% for all the systems at the lower 
concentrations tested. At the highest concentration (corresponding to the CMC) only the 
conjugates bearing shorter hydrophilic chains (CuPMOXA10 and CuPMOXA20) showed a decrease 
in cell viability. 
In particular as cells, macrophages were used in order to verify whether micelles are able to 
induce cell toxicity.  At different concentrations, none of the micelles showed toxicity against 
macrophages except for conjugates with PMOXA10 and PMOXA20. These latter, at their CMC are 
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able to induce cellular death probably because of their tendency to form aggregates dangerous for 
cells.  
 
 
 
Figure 37.  MTS cytotoxicity results on macrophages RAW 264.7 cell line treated with different 
concentrations of the curcumin-conjugates. 
 
 
 
3.6 Conclusions and outlooks 
New polymeric prodrugs of Curcumin were synthesized. A new class of polymer, poly-2-methyl-2-
oxazolines, was used in order to create a valid alternative to the use of common polymers as PEGs.  
Five amino terminated PMOXA with different chain length of their backbone were synthesized and 
completely characterized. Coupling with Curcumin was carried out and five new prodrugs systems 
were created. Such systems are able to self assemble in water as well as in physiological like 
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conditions because of the hydrophic interactions of Curcumin moieties. Each type of micelles was 
characterized using DLS and TEM in order to investigate how the length of polymeric backbone 
could influence the self assembly process. In particular, differences in terms of size were observed 
and an opposite trend was observed between diameter and chain length. For each type of micelle 
the CMC was indentified and conjugate Curcumin-PMOXA30 showed the higher ability to self 
assemble in aqueous solution.  Physical and chemical stability over one month was tested. Except 
for Curcumin-PMOXA10 whose aggregates were identified, for other compound a good stability 
appeared. Curcumin release in physiological like conditions (PBS, pH 7.4, 37°C) was tested and 
Curcumin-PMOXA30 showed the best behaviour over 24 hours because of its ability to release 
around 80-90% of Curcumin. Cytotoxicity assays were carried out, and no evidence of cellular 
death was identified for nanoparticles of Curcumin-PMOXA30, Curcumin-PMOXA50 and Curcumin-
PMOXA100.   
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3.7  Experimental Section  
3.7.1 Materials and methods  
Curcumin was purchased from TCI Europe. Other starting materials and reagents were purchased 
from SigmaAldrich (Milan, Italy), Fluka (Milan, Italy), Merck-Novabiochem (Milan, Italy), Acros 
Organics (Milan, Italy), and were used as received. 2-methyl-2-oxazoline and methyl 
trifluoromethanesulfonate were previously distilled over KOH and CaH respectively. The solvents 
were analytical or synthetic grade and were used without further purification. Dialysis membranes 
were purchased by Spectra and were used as received. 1H-NMR spectra were recorded with a 
Bruker  spectrometer operating at 300 MHz. Chemical shifts (δ) are given in ppm relative to the 
signal of the solvent. UPLC-UV analyses were performed with an Agilent 1290 Infinity LC System 
(Agilent Technologies, Milan, Italy), equipped with binary pump and a diode array detector (190–
500 nm). Fluorescence/UV-Vis spectra were recorded at 37°C with a Perkin-Elmer LS-55 
spectrofluorimeter cell holder. Quartz cells with an optical pathlenght of 10 mm were used for 
measurement of both absorption  fluorescence and UV-Vis spectra. 
 
 
Cell culture and mts/fluorescence microscopy experiments materials Cells were cultured in 
DMEM medium (Gibco 11965-092) supplemented with 10% of FBS and 1% penicillin-streptomycin. 
For cytotoxicity studies: two Dulbecco's Modified Eagle media were obtained from Invitrogen: a) 
the DMEM, High Glucose, GlutaMAX™, Pyruvate (Catalog No. 31966021), herein named as “DMEM 
with phenol red” b) the DMEM, High Glucose, no Glutamine, no Phenol Red (Catalog No. 
31053028), herein named as “DMEM without phenol red”. Also Penicillin-Streptomycin Solution, 
liquid (Catalog No.15140122), herein named as “PenStrep”, Sodium Pyruvate 100 mM Solution 
(Catalog No. 11360039), herein named as “Sodium Pyruvate”, GlutaMAXTM Supplement (Catalog 
No. 35050038), herein named as “GlutaMAX”, Foetal Bovine Serum (FBS, Catalog No. 10270106) 
and Phosphate Buffered Saline (PBS) (1x) (Catalog No. 10010015) were obtained from Invitrogen.  
The DMEM with phenol red was supplemented with 1 vol% PenStrep and 10 vol% FBS and used for 
normal cell growth. The DMEM without phenol red was used as “complete” and as “serum-free” 
medium. The “complete” medium contained 1 vol% PenStrep, 1 vol% Sodium Pyruvate, 2 vol% 
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GlutaMAX and 10 vol% FBS. The “serum-free” medium had similar composition with the complete 
medium but with 0 vol% FBS. 
 
 
Dynamic light scattering (DLS) The size distribution of polymeric micelles was investigated with 
DLS using a Nano-ZS (Malvern Instruments Inc., U.K.). Each sample was diluted in Milli-Q water in 
order to obtain a solution at specific micelle’s CMC. The intensity-mean z-averaged particle size 
(effective diameter) and the polydispersity index (PDI) obtained from cumulant analysis were 
given to reflect hydrodynamic diameters of Curc-PMOXA micelles. 
 
Transmission Electron microscopy (TEM) micrographs were recorded on a Philips CM12 operating 
at 100 kV. Colloidal solution of each sample were deposited on 200 mesh carbon-coated copper 
grids previously submitted to negative glow discharge. Solution was allowed to absorb for 1 
minute, then the excess fluid was removed. To enhance contrast, all specimens were negatively 
stained for 30 seconds using a 2% aqueous solution of uranyl acetate.  
 
Drug release studies To investigate the percentage of released Curcumin from each type of 
micelle  UV (Varian Cary® 50-Uv-vis) was used. Each micelle was dissolved in 1 mL of PBS (pH: 7.4) 
at its specific CMC. Every sample was heated at 37°C for 24 hours. Every hour a specific aliquot 
(100 L) was taken, and was diluted in a quartz cuvette with DMSO (900 L). A Uv-Vis spectrum 
between 300 and 700 nm was acquired. The percentage of released Curcumin was calculated 
following the decrease in the absorption band of Curcumin at 430 nm over time. 
 
 
Mts cytotoxicity/fluorescence microscopy studies protocol In 96-well plates 12500 cells per well 
(i.e. 12.5*104 cells/mL in DMEM+10%FBS without phenol red) were used and seed 100  for 24 h 
prior to experiment. During the experiment a mixture of sterilized Milli-Q with serum-free DMEM 
(without phenol red) in volume ratio 1:3 and incubate for 6 h (100 uL per well) as negative control 
was used. After this time, 20 L MTS solution were added. After 3 hours, the absorbance was read 
using a multi-plate reader set at 490 nm. 
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3.7.2 Synthesis and analytical data of compounds 3a-e 
 General procedure for the synthesis of poly-2-methyl-2-oxazolines of different length 2-methyl-
2-oxazoline previously distilled (n eq.) was dissolved in dry ACN and cooled to 0°C under Ar 
atmosphere. Methyl trifluoromethanesulfonate (1 eq.) was added to the mixture and solution was 
heated to 70°C.  Reaction was stirred for 20 hours under Ar atmosphere then was warmed up to 
room temperature. Ammonia in dry THF solution (3 eq.) was added and stirring was maintained 
for 48 hours. Solvent was evaporated under vacuum, solid was  dissolved in mq water and dialyzed 
against water for 48 hours. Aqueous solution was freeze dried in order to afford a white solid.  
 
Poly-2-methyl-2-oxazoline850 (3a):  Yield: 75%. 1H NMR (300 MHz, D2O) δ 3.83 (m, 2H), 3.60 (m, 
40H), 3.16 – 2.87 (m, 3H), 2.20 – 1.97 (m, 30H) ppm. 
 
 
Poly-2-methyl-2-oxazoline1700 (3b): Yield: 80%. 1H NMR (300 MHz, D2O) δ 3.86-3.81 (m, 2H), 
3.64-3.54 (m, 80H), 3.16 – 2.87 (m, 3H), 2.20 – 1.97 (m, 60H) ppm. 
 
Poly-2-methyl-2-oxazoline2550 (3c):  Yield: 80%. 1H NMR (300 MHz, D2O) δ 3.85-3.81 (m, 2H), 3.64-
3.53 (m, 120H), 3.10-2.93 (m, 3H), 2.13-2.06 (m, 90H) ppm. 
 
Poly-2-methyl-2-oxazoline4250 (3d):  Yield: 75%. 1H NMR (300 MHz, D2O) δ 3.84 – 3.22 (m, 200H), 
3.09-2.92 (m,  3H), 2.33 – 1.80 (m, 150H) ppm. 
 
Poly-2-methyl-2-oxazoline8500 (3e): Yield: 78%.  1H NMR (300 MHz, D2O) δ 3.96 – 3.16 (m, 400H), 
3.09-2.92 (m,  3H), 2.23 – 1.76 (m, 300H) ppm. 
 
 
3.7.3 Synthesis and analytical data of conjugates 4a-e 
General procedure for the synthesis of curcumin-poly-2-methyl-2-oxazoline conjugates  bis(4-
nitrophenyl) carbonate (1.2 eq.) in was dissolved in CAN and the mixture was cooled at 0°C.  
PMOXAn (1 eq.) and 4-(dimethylamino)pyridine (1.2 eq.) were dissolved in ACN  and this fresh 
 86 
 
solution was added dropwise to the mixture. After stirring for 12 hours at room temperature a 
fresh solution of Curcumin (1 eq.) and 4-(dimethylamino)pyridine (1 eq.) in THF was added 
dropwise and mixture was warmed up to 50°C for 24 hours. Solvent was evaporated under 
vacuum, solid was dissolved in mq water and dialyzed for 48 hours. Aqueous solution was dried in 
order to afford a yellow solid. 
 
 
Curcumin-Poly-2-methyl-2-oxazoline850 (4a): Yield: 60%.  1H NMR (300 MHz, DMSO) δ 8.15 (d, J = 
7.6 Hz, 2H), 7.55 (d, J = 15.9 Hz, 2H), 7.32 (s, 2H), 7.15 (d, J = 8.0 Hz, 2H), 6.91 – 6.70 (m, 2H), 6.07 
(s, 1H), 3.83 (s, 6H), 3.41 (m, 40H), 3.02 – 2.89 (m, 3H), 2.09 – 1.86 (m, 30H). 
 
 
Curcumin-Poly-2-methyl-2-oxazoline1700 (4b): Yield: 53%. 1H NMR (300 MHz, DMSO) δ 7.54 (d, J 
= 15.8 Hz, 2H), 7.33 (s, 2H), 7.14 (d, J = 8.2, 2H), 6.91 – 6.69 (m, 3H), 6.06 (s, 1H), 3.83 (s, 6H), 3.36 
(m, 80H), 2.95 (m, 3H), 1.99 (m, 60H). 
  
 
Curcumin-Poly-2-methyl-2-oxazoline2550 (4c): Yield: 65%.  1H NMR (300 MHz, DMSO) δ 8.09 (d, J 
= 6.2 Hz, 2H), 7.54 (d, J = 15.8 Hz, 2H), 7.31 (s, 2H), 7.14 (d, J = 8.0 Hz, 3H), 6.78 (m, 2H), 6.05 (s, 
1H), 3.83 (s, 6H), 3.40 (m, 120H), 2.99 – 2.90 (m, 3H), 1.99 (m, 90H). 
 
Curcumin-Poly-2-methyl-2-oxazoline4250 (4d): Yield: 52%.  1H NMR (300 MHz, DMSO) δ 7.59 (dd, 
J = 27.8, 11.0 Hz, 2H), 7.42 – 7.27 (m, 2H), 7.22 – 6.92 (m, 2H), 6.80 (m, 3H), 6.06 (s, 1H), 3.84 (s, 
6H), 3.40 (m, 200H), 2.96 (m, 3H), 2.13 – 1.88 (m, 150H). 
 
Curcumin-Poly-2-methyl-2-oxazoline8500 (4e): Yield: 50%. 1H NMR (300 MHz, DMSO) δ 8.15 – 6.64 
(m, 9H), 6.09 (s, 1H), 3.42 (m, 400H), 2.96 (m, 1H), 1.93 (m, 300H). 
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